document incorporate reference document proxy statement annual meeting shareholder hold file iii security exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item reserve item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm item change disagreement accountant account financial disclosure item control procedure management report item information item disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule item summary signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine include biologic therapy vaccine animal health product company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner june merck complete spinoff spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner product sale total company sale include sale company pharmaceutical product sale animal health product follow million total sale pharmaceutical keytruda gardasilgardasil lagevrio januviajanumet proquadmmr iivarivax bridion alliance revenue lynparza alliance revenue lenvima rotateq simponi animal health livestock companion animal revenue alliance revenue represent merck share profit product sale net cost sale commercialization cost revenue primarily comprise miscellaneous corporate revenue include revenue hedging activity revenue thirdparty manufacture arrangement table content pharmaceutical pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder human health vaccine product consist preventive pediatric adolescent adult vaccine certain product company franchise follow oncology keytruda pembrolizumab company antipd program death receptor therapy monotherapy treatment certain patient cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc melanoma merkel cell carcinoma microsatellite instability high msih mismatch repair deficient dmmr cancer solid tumor include msihdmmr colorectal cancer crc msihdmmr advanced endometrial carcinoma primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh cancer solid tumor urothelial carcinoma include nonmuscle invasive bladder cancer keytruda approve treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy human epidermal growth factor herpositive gastric gej adenocarcinoma combination platinumand fluoropyrimidinebase chemotherapy esophageal gej carcinoma combination chemotherapy bevacizumab advanced cervical cancer combination chemotherapy locally recurrent unresectable metastatic triplenegative breast cancer tnbc combination axitinib advance renal cell carcinoma rcc keytruda approve certain patient highrisk earlystage tnbc combination chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery keytruda approve monotherapy adjuvant treatment certain patient rcc certain patient completely resect stage iib iic iii melanoma adjuvant treatment follow resection platinumbase chemotherapy adult patient stage iiia nsclc addition company recognize alliance revenue relate sale lynparza olaparib oral poly adpribose polymerase parp inhibitor certain type advance recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancer alliance revenue relate sale lenvima lenvatinib oral receptor tyrosine kinase inhibitor certain type thyroid cancer rcc hcc combination everolimus certain patient advance rcc combination keytruda certain patient advance endometrial carcinoma advance rcc alliance revenue relate reblozyl luspaterceptaamt treatment certain type anemia vaccine gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain disease cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease vaqta hepatitis vaccine inactivated indicate prevention disease cause hepatitis virus person month age old hospital acute care bridion sugammadex injection medication reversal type neuromuscular block agent surgery prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipient allogeneic hematopoietic stem cell transplant dificid fidaxomicin treatment difficileassociate diarrhea primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infection noxafil posaconazole antifungal agent prevention certain invasive fungal infection invanz ertapenem injection antibiotic treatment certain bacterial infection cancida caspofungin acetate injection antifungal agent treatment certain fungal infections zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infection cardiovascular adempas riociguat cardiovascular drug treatment chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension certain patient verquvo vericiguat medicine reduce table content risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic certain adult symptomatic chronic heart failure reduce ejection fraction virology lagevrio investigational oral antiviral covid medicine available emergency use authorization eua isentressisentress raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection neuroscience belsomra suvorexant orexin receptor antagonist indicate treatment insomnia characterize difficulty sleep onset andor sleep maintenance immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease remicade infliximab treatment inflammatory disease company market europe russia trkiye diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete animal health animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine health management solution service extensive suite digitally connect identification traceability monitoring product principal product segment include livestock product nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorder cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiency beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type kill baculovirus vector vaccine line infectious disease swine nobilisinnovax live marek disease vector vaccine line poultry paracox coccivac coccidiosis vaccine exzolt systemic treatment poultry red mite infestation slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solution animal identification monitor traceability companion animal product bravecto line oral topical parasitic control product include original bravecto fluralaner product dog cat week bravecto fluralaner onemonth monthly product dog bravecto plus fluralanermoxidectin twomonth product cat sentinel line oral parasitic product dog include sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tab milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine line flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabete mellitus treatment dog cat panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use animal regumate altrenogest fertility management horse prestige vaccine line horse scalibor deltamethrinexspot protect bite flea tick mosquitoe sandfly sure petcare product companion animal identification wellbee include microchip pet recovery system home discussion sale company product item management discussion analysis financial condition result operation table content product approval set forth summary significant product approval receive company product date approval european commission approve keytruda monotherapy adjuvant treatment adult rcc increase risk recurrence follow nephrectomy follow january nephrectomy resection metastatic lesion japans ministry health labor welfare mhlw approve keytruda plus february lenvima radically unresectable metastatic rcc mhlw approve keytruda treatment adult patient advance recurrent february tmbh solid tumor progress chemotherapy limited use difficult treat standard care food drug administration fda approve keytruda single agent treatment patient advance endometrial carcinoma msih dmmr march disease progression follow prior systemic therapy set candidate keytruda curative surgery radiation approve keytruda combination chemotherapy april bevacizumab treatment persistent recurrent metastatic cervical cancer certain adult tumor express pdl approve keytruda monotherapy treatment certain patient unresectable metastatic msihdmmr colorectal gastric small intestine biliary cancer april advanced recurrent msihdmmr endometrial carcinoma approve keytruda combination chemotherapy neoadjuvant treatment continue monotherapy adjuvant treatment surgery adult locally advanced earlystage tnbc high risk recurrence approve keytruda monotherapy adjuvant treatment adult adolescent aged year old stage iib iic melanoma undergone complete resection additionally approve expand indication advance unresectable june metastatic melanoma stage iii melanoma lymph node involvement adjuvant treatment follow complete resection include adolescent patient age year old mhlw approve keytruda monotherapy adjuvant treatment certain august patient rcc increase risk recurrence follow nephrectomy follow nephrectomy resection metastatic lesion mhlw approve keytruda combination chemotherapy neoadjuvant treatment continue monotherapy adjuvant treatment surgery patient september hormone receptornegative hernegative breast cancer high risk recurrence keytruda mhlw approve keytruda combination chemotherapy bevacizumab treatment patient advance recurrent cervical cancer prior september chemotherapy amenable curative treatment mhlw approve keytruda monotherapy adjuvant treatment patient september stage iib iic melanoma complete resection china national medical products administration nmpa approve keytruda october monotherapy treatment patient hcc previously treat sorafenib oxaliplatinbase chemotherapy nmpa approve keytruda treatment patient highrisk earlystage tnbc tumor express pdl combination chemotherapy neoadjuvant treatment november continue monotherapy adjuvant treatment surgery table content nmpa grant emergency conditional approval lagevrio treatment mild lagevrio december moderate covid adult risk progress severe covid fda approve lynparza adjuvant treatment adult patient deleterious suspect deleterious germline brcamutate hernegative highrisk early breast march cancer treat neoadjuvant adjuvant chemotherapy mhlw approve lynparza adjuvant treatment patient august mutate hernegative high recurrent risk breast cancer approve lynparza monotherapy combination endocrine therapy adjuvant treatment adult patient germline brcamutation august negative highrisk early breast cancer previously treat neoadjuvant adjuvant lynparza chemotherapy nmpa approve lynparza firstline maintenance treatment adult patient advance epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbase chemotherapy combination bevacizumab september cancer associate homologous recombination deficiency hrdpositive status approve lynparza combination abiraterone prednisone prednisolone treatment adult patient metastatic castrationresistant prostate december cancer mcrpc chemotherapy clinically indicate fda approve expand indication vaxneuvance pneumococcal valent conjugate vaccine include child week year age vaxneuvance indicate active immunization prevention invasive disease cause june streptococcus pneumoniae serotype individual week age old vaxneuvance mhlw approve vaxneuvance prevention infection cause streptococcus september pneumoniae elderly adult consider increase risk disease cause streptococcus pneumoniae approve expand indication vaxneuvance include active immunization prevention invasive disease pneumonia acute otitis medium cause october streptococcus pneumoniae infant child adolescent week year age jointly develop collaboration ridgeback biotherapeutic jointly develop commercialize worldwide collaboration astrazeneca competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result payment royalty recognition impairment charge respect intangible asset associate certain product pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company wellpositione compete search technological innovation company active acquire table content marketing product external alliance license arrangement collaboration refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product competitor product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access change health care system health care reform enact prior year increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company sale performance negatively affect costreduction measure take government party low health care cost biden administration congress continue discuss legislation design control health care cost include cost drug company anticipate action additional action future continue negatively affect sale profit united states company face increase pricing pressure manage care organization government agency program negatively affect company sale profit margin include practice manage care organization federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act aca american rescue plan act american rescue plan act inflation reduction act inflation reduction act federal state government year pursue method reduce cost drug vaccine pay example federal state law require company pay specify rebate medicine reimburse medicaid provide discount medicine purchase certain state federal entity department defense veteran affairs public health service entity hospital serve disproportionate share low income uninsured patient additionally consolidation integration health care provider major factor competitive marketplace pharmaceutical product health plan pharmacy benefit manager pbms consolidate few large entity enhance purchasing strength importance private thirdparty insurer government employ formulary control cost negotiate discount price exchange formulary inclusion failure obtain timely adequate pricing formulary placement merck product obtain placement unfavorable pricing adversely affect revenue addition formulary tier copay differential private health insurance company selfinsure employer increase costshare require beneficiary particularly brand pharmaceutical biotechnology product private health insurance company increasingly impose utilization management tool clinical protocol require prior authorization brand product require patient fail generic product permit access brand medicine management tool treatment area payor take position multiple brand product therapeutically comparable payor market concentrate company face great pricing pressure private thirdparty payor order provide information company pricing practice company annually post website pricing transparency report report provide company average annual list price net price increase average discount company portfolio date company gross sale reduce result rebate discount return legislative change congress pass inflation reduction act make significant change drug cover pay medicare program include creation financial penalty drug price rise fast rate inflation redesign medicare program require manufacturers bear table content liability certain drug benefit government pricesette certain medicare drug start medicare drug start longterm implication inflation reduction act remain uncertain subject factor include manner department health human service decides implement statute expert analyst industry outside predict law harm innovation pharmaceutical industry result few new treatment develop approve time merck work mitigate potentially harmful effect law innovation addition congress pass american rescue plan act include provision eliminate statutory cap rebate drug manufacturer pay medicaid begin january rebates act discount list price eliminate cap mean manufacturer discount pay medicaid increase prior change manufacturer require pay average manufacturer price amp rebate state medicaid program medicaidcovere drug result provision begin possible manufacturer pay state medicaid programs rebate receive sale particular product change present risk merck future drug high medicaid utilization rebate exposure amp company face increase pricing pressure state look exert great influence price prescription drug number state pass pharmaceutical price cost transparency law law typically require manufacturer report certain product price information financial datum state law require manufacturer provide advance notification price increase company expect state continue focus pharmaceutical pricing increasingly shift aggressive price control tool prescription drug affordability board authority conduct affordability review establish upper payment limit regulatory change november department health human service office inspector general issue final rule effective january eliminate antikickback statute safe harbor rebate pay medicare plans pbms behalf plan congress delay implementation final rule january pende federal legislation repeal entirely company anticipate effect change way currently contract new framework significantly alter way business plan sponsor pbms behalf plan rulemake establish effective january new safe harbor point sale discount pharmacy counter new safe harbor certain service arrangement pharmaceutical manufacturer pbms pharmaceutical industry consider potential source saving legislative administrative proposal debate enact type revenue generating cost saving proposal include additional direct price control european union effort health care cost containment remain intense european union company face competitive pricing pressure result generic biosimilar drug addition majority country attempt contain drug cost engage reference pricing authority examine pre determined market publish price drug reference pricing compare product price market external reference pricing compare product price product national class internal reference pricing authority use price datum set new local price brandname drug include company drug guideline examine reference pricing usually set local market change pursuant local regulation member states establish freeprice system regulate pricing drug profit control plan seek negotiate set price base costeffectiveness product assessment offer therapeutic benefit product relevant class downward pressure health care cost general particularly prescription drug intense result increasingly high barrier erect entry new product member states crossborder import lowprice market exert competitive pressure reduce pricing member state additionally member states power restrict range pharmaceutical product national health insurance system provide reimbursement pricing reimbursement plan vary widely member state member state member state provide drug product marketed reimbursement price agree member states require completion additional study compare cost effectiveness particular product candidate available therapy socalle health technology assessment hta order obtain reimbursement pricing approval hta pharmaceutical product increasingly common price reimbursement procedure table content member states hta process govern national law country involve assessment costeffectiveness public health impact therapeutic impact andor economic social impact use give pharmaceutical product national health care system individual country conduct ultimately hta measure add value new health technology compare exist one outcome hta specific pharmaceutical product influence pricing reimbursement status grant pharmaceutical product regulatory authority individual member states negative hta company product mean product reimbursable force company reduce reimbursement price offer discount rebate negative hta leading recognize hta body undermine company ability obtain reimbursement relevant product outside jurisdiction example member states develop hta mechanism rely extent hta perform country develop hta framework inform pricing reimbursement decision hta procedure require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement obtain reimbursement pricing approval member states company require conduct study compare costeffectiveness company product candidate therapy consider local standard care assurance member state allow favorable pricing reimbursement market access condition company product feasible conduct additional costeffectiveness study require japan japan pharmaceutical industry subject governmentmandate annual price reduction pharmaceutical product certain vaccine furthermore government order repricing specific product determine use product exceed certain threshold define applicable pricing rule addition merck product medical action composition product subject market expansion repricing merck product subject repricing meet exception criterion governmentmandate price reduction occur april china companys business china grow rapidly past year importance china company overall pharmaceutical vaccine business increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company current inline product absence trade impediment adverse pricing control recent year chinese government introduce implement number structural reform accelerate shift innovative product reduce cost multiple new policy introduce government improve access new innovation reduce complexity regulatory filing accelerate review approval process lead significant increase number new product approve year mechanism drug add government national reimbursement drug list nrdl evolve inclusion require price negotiation impact outlook market select brand drug add nrdl average price reduction new nrdl recently complete new entry average price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution volume base procurement vbp government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward emerge market company focus emerge market addition china continue government emerge market focus constrain health care cost enact price control measure impact intellectual property include exceptional case threat compulsory license aim pressure price innovative pharmaceutical result constrain market access innovative medicine company anticipate pricing pressure market access challenge continue future vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability change trade sanction embargo significant currency fluctuation control financial crisis limit change availability funding health care credit worthiness health care partner hospital table content development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address global cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe wellpositione respond evolve health care environment market force regulation pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market time fda commit expedite development review product bear breakthrough therapy designation accelerate regulatory review process medicine designation fda undertake effort bring generic competition market efficiently timely manner adopt directive legislation concern classification approval marketing labeling advertising manufacture wholesale distribution integrity supply chain pharmacovigilance safety monitor medicinal product human use provide mandatory standard supplemented implement additional regulation member states particular regulator approve product subject number postauthorization condition example typical postauthorization commitment include additional pharmacovigilance conduct clinical trial establishment patient registry physician patient education control distribution prescribing arrangement noncompliance postauthorization condition pharmacovigilance obligation lead regulatory action include variation suspension withdrawal marketing authorization enforcement regulatory action include imposition financial penalty company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize collaboration key stakeholder role play help ensure science advance health care product accessible affordable company commit ensure reliable safe global supply quality medicine vaccine develop testing implement innovative solution address barrier access affordability medicine vaccine company approach design enable serve great number patient today meeting need patient future company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care company systematically evaluate pipeline candidate identify potential address significant public health burden unmet medical need underserve health care setting product continue evaluate potential life cycle account change external environment company collaborate different stakeholder table content include private governmental multilateral nonprofit organization design deliver sustainable solution help address access challenge payer provider patient level addition innovative social investment include philanthropic program impact investing merck help strengthen health system build capacity particularly underresourced community merck patient assistance program provide certain medicine adult vaccine free people prescription drug health insurance coverage company assistance afford merck medicine vaccine globally merck substantial contribution access health key initiative include product donation humanitarian assistance lowincome country medical outreach program mectizan donation program long run diseasespecific drug donation program kind support elimination neglect tropical disease onchocerciasis lymphatic filariasis additionally merck mother company provide fund scientific business acuman help global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent grantmaking organization support variety organization dedicate address systemic barrier health equity privacy data protection company subject significant number privacy datum protection law regulation globally place restriction company ability transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include general data protection regulation gdpr impose penalty global revenue gdpr related implement law individual member states govern collection use personal health datum personal datum gdpr increase responsibility liability relation personal datum company process impose number strict obligation restriction ability process include collection analysis transfer personal datum include health datum clinical trial adverse event report gdpr include requirement relate consent individual personal data relate information provide individual prior process personal datum personal health datum notification datum processing obligation national datum protection authority security confidentiality personal datum gdpr prohibits transfer personal data country outside consider provide adequate level data protection include datum controller meet specific requirement follow schrems decision court justice considerable uncertainty permissibility international data transfer gdpr light implication decision company face difficulty transfer personal datum country company diligently enter euapproved standard contractual clause vendor supplier collaboration partner clinical trial site order facilitate lawful transfer personal datum addition president biden issue executive order october address datum privacy concern raise schrems decision introduce measure safeguard oversight personal data collection signal intelligence activity provide individual redress mechanism data protection concern certainty international transfer personal datum euus datum privacy framework successor invalidated euus privacy shield come way new adequacy decision issue draft form commission december expect come force mid remain likely new adequacy decision contest privacy advocate subject legal review failure comply requirement gdpr related national datum protection law member states result significant monetary fine administrative penalty civil liability claim individual personal datum process datum protection authority different member state implement certain variation enforce gdpr national datum protection law differently introduce additional national regulation guideline add complexity process personal datum guidance develop level national level individual member state concern implementation compliance practice update revise grow trend require public disclosure clinical trial datum add complexity obligation relate processing health datum clinical trial fail comply obligation lead government enforcement action significant penalty company harm reputation adversely impact business operating result uncertainty interplay table content different regulatory framework add complexity company face regard datum protection regulation august china pass personal information protection law pipl aim standardize handle personal information china effective november pipl currently apply process personal information natural person china process personal information outside china purpose provide product service china analyze activity individual china similar gdpr pipl contain unique requirement find gdpr company develop implement comprehensive plan ensure compliance pipl relate data localization cross border transfer complete pende forthcoming guidance cyberspace administration china additional law regulation enact comprehensive datum protection act california virginia colorado utah connecticut canada europe asia latin america increase enforcement litigation activity develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolving requirement risk facilitate transfer personal information international border distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pbms institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer farmer pet owner patent trademark license patent protection consider aggregate material importance company marketing product major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term period patent product regulatory review fda provide additional month pediatric market exclusivity attach product supplementary protection certificate spc japan provide additional term pediatric study attach market exclusivity unrelated patent term table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection japan china include potential patent term extension pte spc indicate follow market product product year expiration year expiration year expiration japan year expiration china januvia expire expire expire janumet expired expire expire janumet expire expired isentress expire simponi lenvima spc expire bridion expire bravecto pende pte patent spcs gardasil expire expire gardasil patent spc keytruda lynparza pending pte patent spcs zerbaxa patent spc adempas belsomra prevymis pende pte patent spc verquvo pende pte vaxneuvance pende pte patent patent delstrigo pende pte patent spc pifeltro pende pte patent spc recarbrio pending pte patent spc pende pte welireg pende pte note compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability currently market approval date represent expiration date follow country france germany italy spain major market spc application file grant major markets patent expiry date spc expiry date list pte system japan allow patent extend provide later approval direct different indication previous approval result multiple pte approval give patent expiration date result favorable court ruling settlement agreement relate later expire patent direct specific sitagliptin salt form product company expect product lose market exclusivity end likely exclusivity extend expiry date reflect approve product includes grant pte tablet japan company marketing right japan china distribution agreement janssen pharmaceuticals inc expire october global strategic oncology collaboration eisai ltd eligible month pediatric exclusivity global strategic oncology collaboration astrazeneca commercialize worldwide collaboration bayer company marketing right company marketing right japan china table content company follow key patent protection drug candidate review fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration gefapixant company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration sotatercept mka doravirine islatravir pende pte doravirine mka quavonlimab pembrolizumab mka vibostolimab pembrolizumab mka favezelimab pembrolizumab clesrovimab lagevrio pneumococcal vaccine mka pembrolizumab hyaluronidase subcutaneous biologic product sotatercept eligible year datum exclusivity approval receive emergency use authorization fda treatment highrisk adult mild moderate covid note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product expiration compound patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive laterexpire patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek country reform patent relevant law implementation international treaty information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold table content research development company business characterize introduction new product new use exist product strong research development program december approximately people employ company research activity company prioritize research development effort focus candidate believe represent breakthrough science unmet medical need difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit ensure externally source program remain important component pipeline strategy focus supplement internal research acquisition license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company clinical pipeline include candidate multiple disease area include cancer cardiovascular disease metabolic disease infectious disease neuroscience respiratory disease vaccine development human health product industry practice government regulation foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study provide additional data safety immunogenicity andor effectiveness finally phase trial conduct intended population licensure provide datum immunogenicity andor effectiveness safety support application regulatory approval successful company submit regulatory filing appropriate regulatory agency fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant table content priority review standard review pursuant prescription drug user fee act pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review special designation grant give application product designate breakthrough therapy eligible priority review covid public health crisis secretary health human service exercise statutory authority determine public health emergency exist declare circumstance justify emergency use drug biological product authorize fda effect declaration enable fda issue emergency use authorization euas permit distribution use specific medical product absent ndabla submission approval include product treat prevent disease condition cause sarscov virus subject term euas fda certain finding grant eua include reasonable believe base totality evidence drug biologic effective know potential benefit term eua outweigh know potential risk additionally fda find adequate approve available alternative emergency use authorize drug biologic fda revise revoke eua circumstance justify issuance long exist criterion issuance long meet circumstance revision revocation appropriate protect public health safety primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member states outside company submit marketing application national regulatory authority example ministry health labour welfare japan national medical products administration china health canada agncia nacional vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline market approval time long regulatory authority require approval major market issuance certificate pharmaceutical product market initiate local review process table content research development update company currently candidate regulatory review internationally latestage clinical development lagevrio investigational oral antiviral medicine treatment mild moderate covid adult risk progress severe disease merck develop lagevrio collaboration ridgeback biotherapeutic ridgeback fda grant emergency use authorization eua lagevrio december issue february authorize lagevrio treatment adult current diagnosis mildtomoderate covid high risk progression severe covid include hospitalization death alternative covid treatment option approve authorize fda accessible clinically appropriate authorization base phase moveout trial lagevrio approve use authorize duration declaration circumstance exist justify authorization emergency use food drug cosmetic act authorization terminate revoke soon november ema issue positive scientific opinion lagevrio intend support national decision make possible use lagevrio prior marketing authorization october ema initiate rolling review lagevrio treatment covid adult february merck ridgeback announce committee medicinal product human use chmp ema recommend refusal marketing authorization lagevrio merck ridgeback appeal decision request reexamination chmp opinion application regulatory body worldwide underway october merck provide update new clinical nonclinical study lagevrio preliminary analysis university oxford panoramic study conduct highlyvaccinate adult year age show evidence difference lagevrio add usual care compare usual care reduction hospitalization death day primary endpoint meet incidence hospitalization death day low overall main secondary endpoint time selfreporte recovery panoramic study day short lagevrio group compare usual care group addition use lagevrio associate early recovery wide range symptom measure compare usual care group additionally analysis realworld datum separate study conduct investigator israel know clalit study show cohort nonhospitalize highrisk patient lagevrio reduced hospitalization mortality covid patient year evidence benefit find young adult age year merck report result separate nonclinical month carcinogenicity study transgenic mouse demonstrate lagevrio carcinogenic dose test gefapixant investigational orally administer selective receptor antagonist treatment refractory chronic cough unexplained chronic cough adult review fda ema marketing application gefapixant base result cough cough clinical trial january fda issue complete response letter crl merck nda gefapixant crl fda request additional information relate cough counting system assess efficacy crl relate safety gefapixant company perform additional analysis anticipate submit information fda half response crl review period extend pende receipt additional information company merck plan submit information ema half keytruda antipd therapy approve treatment cancer clinical development expand indication approval result broad clinical development program currently consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include biliary estrogen receptor positive breast cancer cervical colorectal cutaneous squamous cell endometrial esophageal gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung small cell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial currently phase clinical development trial plan cancer keytruda review fda treatment patient previously treat advanced hcc submission base datum phase keynote trial supportive datum keynote keynote trial keytruda approve indication fda accelerate approval process submission convert accelerate approval regular approval keytruda priority review fda use combination padcev enfortumab vedotinejfv treatment certain patient locally advanced metastatic urothelial cancer eligible receive cisplatincontaine chemotherapy fda set pdufa date april supplemental blas table content keytruda pedcev combination regiman grant breakthrough therapy designation fda february application support efficacy safety datum phase trial know keynote dose escalationcohort cohort results dose escalationcohort publish journal clinical oncology result cohort present latebreaking session european society medical oncology congress keytruda review fda treatment adult pediatric patient recurrent locally advanced metastatic merkel cell carcinoma submission base datum phase keynote trial keytruda approve indication fda accelerate approval process submission convert accelerate approval regular approval additionally keytruda review fda treatment adult pediatric patient unresectable metastatic microsatellite instabilityhigh msih mismatch repair deficient dmmr solid tumor determine fdaapprove test progress follow prior treatment satisfactory alternative treatment option submission base datum phase keynote trial supportive datum keynote keynote trial keytruda approve indication fda accelerate approval process submission convert accelerate approval regular approval keytruda review adjuvant treatment patient stage iiia nsclc follow complete surgical resection submission base datum pivotal phase keynote trial know eortclcgetop pearl keytruda review japan treatment patient relapse refractory pmblc submission base datum phase keynote study phase keynotea study january merck announce stop phase keynote trial investigate keytruda combination enzalutamide androgen deprivation therapy adt treatment patient metastatic hormonesensitive prostate cancer merck discontinuing study base recommendation independent datum monitor committee dmc review datum plan interim analysis interim analysis keytruda combination enzalutamide adt demonstrate improvement overall survival radiographic progressionfree survival trial dual primary endpoint compare placebo plus enzalutamide adt datum study present upcoming medical meeting lynparza oral parp inhibitor currently approve certain type advance recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancer codevelope multiple cancer type collaboration astrazeneca plc august fda grant priority review supplemental nda lynparza combination abiraterone prednisone prednisolone treatment adult patient mcrpc supplemental nda base result phase propel trial present american society clinical oncology genitourinary cancer symposium later publish nejm evidence fda initially set pdufa date fourth quarter december fda extend pdufa date month provide time review submission lynparza review japan treatment certain patient mcrpc base propel trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai ltd eisai merck eisai study keytruda plus lenvima combination leap lenvatinib pembrolizumab clinical program include study different tumor type biliary cancer crc endometrial carcinoma esophageal cancer gastric cancer hcc hnscc melanoma pancreatic cancer prostate cancer nsclc smallcelllung cancer sclc rcc company program phase clinical development mka coformulation quavonlimab merck novel investigational antictla antibody pembrolizumab evaluate treatment rcc subcutaneous pembrolizumab evaluate comparability intravenous formulation pembrolizumab nsclc subcutaneous mka coformulation pembrolizumab hyaluronidase evaluate comparability intravenous formulation pembrolizumab nsclc mka coformulation favezelimab merck novel investigational antilag therapy pembrolizumab evaluate treatment crc hematological malignancy table content welireg belzutifan hypoxiainducible factor hif inhibitor evaluate supplemental indication treatment patient rcc tukysa tucatinib small molecule tyrosine kinase inhibitor treatment herpositive cancer development treatment breast cancer colorectal cancer september seagen grant merck exclusive license enter codevelopment agreement merck accelerate global reach tukysa mka coformulation vibostolimab antitigit therapy pembrolizumab evaluate treatment melanoma nsclc sclc december merck announce fda place clinical hold investigational new drug application islatravir programs development treatment prevention hiv infection fdas clinical hold base observation decrease total lymphocyte cell count participant receive islatravir clinical study september merck announce initiate new doravirineislatravir mka phase clinical program treatment people hiv infection new phase study evaluate oncedaily oral combination doravirine lower dose islatravir previously untreated adult switch antiretroviral therapy virologically suppress adult hiv infection phase clinical trial evaluate investigational oral onceweekly combination treatment regimen islatravir gilead science lenacapavir adult hiv infection virologically suppress resume amend protocol low dose islatravir investigational nda islatravir lenacapavir onceweekly treatment regimen remain partial clinical hold study use weekly oral islatravir dose high dose consider revise clinical program additionally merck announce discontinue development oncemonthly oral islatravir prep company remain committed develop compound longacte hiv prevention believe potential nucleoside reverse transcriptase translocation inhibitor nrtti mechanism phase study adult hiv infection assess novel nrtti candidate commence shortly investigational valent pneumococcal conjugate vaccine pcv treatment pneumococcal infection adult june merck announce presentation positive result phase study evaluate safety tolerability immunogenicity pneumococcal vaccinenave adult year age phase year age old phase population meet primary immunogenicity objective welltolerate overall safety profile generally comparable pneumovax age group april merck announce receive breakthrough therapy designation fda prevention invasive pneumococcal disease pneumococcal pneumonia cause streptococcus pneumoniae serotype adult year age old phase trial evaluate ongoing sotatercept investigational activin receptor type iiafc fusion protein evaluate addon stable background therapy treatment pulmonary arterial hypertension pah sotatercept obtain connection merck acquisition acceleron pharma inc october merck announce positive topline result pivotal phase stellar trial evaluate safety efficacy sotatercept treatment pah world health organization group trial meet primary efficacy outcome measure demonstrate statistically significant clinically meaningful improvement minute walk distance mwd measure far patient walk minute secondary efficacy outcome measure achieve statistical significance include outcome measure proportion participant achieve multicomponent improvement define improvement mwd improvement terminal probtype natriuretic peptide level improvement functional class maintenance outcome measure time death occurrence clinical worsen event cognitiveemotional impact domain score pahsympact assess ninth final secondary outcome measure achieve statistical significance result present upcoming american college cardiology annual scientific session company anticipate file sotatercept regulatory authority clesrovimab respiratory syncytial virus rsv monoclonal antibody evaluate prevention rsv medically attend low respiratory tract infection infant certain child year age phase trial currently enrol october merck royalty pharma plc royalty pharma enter funding arrangement royalty pharma pay merck million fund merck development cost phase trial investigational oral phosphodiesterase pdea inhibitor evaluate treatment schizophrenia agreement royalty pharma right decisionmake authority program merck elect advance phase study royalty pharma option provide additional funding development cost million phase trial table content additional funding provide royalty pharma eligible receive future regulatory milestone payment contingent certain marketing approval royalty chart reflect company research pipeline february candidate show phase include date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area respect cancer additional claim line extension formulation inline product show phase cancer cancer cancer ladiratuzumab vedotin lenvima nonsmallcell lung breast biliary nemtabrutinib esophageal pancreatic hematological malignancy gastric prostate quavonlimab head neck smallcell lung nonsmallcell lung melanoma mka quavonlimabpembrolizumab nonsmallcell lung melanoma colorectal prostate dengue fever virus vaccine hepatocellular smallcell lung melanoma welireg hiv infection smallcell lung biliary mkb islatravirmk zilovertamab vedotin colorectal mkd islatravirlenacapavir bladder endometrial hypercholesterolemia breast esophageal gastric hepatocellular nonalcoholic steatohepatitis nash hematological malignancies pancreatic efinopegdutide nonsmallcell lung rare cancer overgrowth syndrome ovarian von hippellindau diseaseassociate tumors miransertib mkp tumors pul arterial hypertension neoplasm malignant biliary pulmonary hypertension left heart disease keytruda bladder sotatercept advanced solid tumor cervical schizophrenia bomedemstat endometrial myeloproliferative disorder gastric thrombosis favezelimab nonsmallcell lung zll limun bpembrolizumab edn orz lia mors tre mat resistant depression esophageal mka vibostolimabpembrolizumab melanoma biliary renal cell bladder smallcell lung breast cervical colorectal colorectal esophageal endometrial melanoma esophageal nonsmallcell lung gastric ovarian head neck renal cell hematological malignancy smallcell lung hepatocellular ovarian prostate prostate boserolimab nonsmallcell lung smallcell lung table content phase phase entry date review antiviral covid new molecular entity certain supplemental filing lagevrio antiviral covid cancer cancer lagevrio keytruda mka quavonlimabpembrolizumab cough secondline hepatocellular cancer renal cell april gefapixant keynote keytruda firstline locally advanced metastatic urothelial carcinoma biliary september keynote cutaneous squamous cell august locally advanced metastatic merkel cell carcinoma gastric keynote hepatocellular adjuvant nonsmallcell lung cancer mesothelioma keynote ovarian december relapse refractory primary mediastinal bcell lymphoma prostate keynotekeynotea jpn smallcell lung pembrolizumab subcutaneous nonsmallcell lung august mka pembrolizumabhyaluronidase subcutaneous lynparza nonsmallcell lung february firstline metastatic prostate cancer mka favezelimabpembrolizumab propel jpn colorectal november hematological malignancies october welireg renal cell february tukysa breast october colorectal august lynparza nonsmallcell lung june smallcell lung december mka vibostolimabpembrolizumab melanoma january footnote smon cea nll develop collaboration lenvima develop combination keytruda eso olo gta uil develop monotherapy andor combination keytruda gastric december fda clinical hold lad mnd mec fda partial clinical hold high dose current clinical trial nonsmallcell lung march phase development cost cofunde aio doravirineislatravir february available emergency use authorization pne lyc cine adult ath ipr me inro ish fod afo tir nth tis thp fic dat aio iru perform additional pulmonary arterial hypertension sotatercept january respiratory syncytial virus clesrovimab november human capital december company approximately employee worldwide approximately employ include puerto rico additionally approximately thirdparty contractor globally approximately company employee fulltime employee globally woman comprise employee individual underrepresented ethnic group comprise workforce company define workforce employee woman comprise member board director additionally company senior management team woman approximately company employee represent collective bargaining group company voluntary turnover rate approximately respectively company recognize employee critical meet need patient customer ability excel depend integrity skill diversity employee party contractor include company temporary worker independent contractor freelancer view fulltime equivalent employee exclude outsource service provider talent acquisition company use comprehensive approach ensure recruit retention leadership development goal systematically execute company hire talented leader achieve improved gender parity representation dimension diversity company provide training table content manager external recruiting organization strategy mitigate unconscious bias candidate selection hiring process addition company utilize comprehensive communication strategy employee brand marketing outreach social medium strategic alliance partnership reach broad pool talent critical business area company hire approximately employee globe channel include company external career site direct passive candidate source diversity partnership employee referral university external source global diversity inclusion diversity inclusion fundamental company success core future innovation company foster globally diverse inclusive workforce employee create environment belong engagement equity empowerment company proactive intentional diversity hire development program advance talent company create competitive advantage leverage diversity inclusion accelerate business performance include foster global supplier diversity integrate diversity inclusion company commercialization strategy leverage employee insight improve performance addition effort company employee business resource group provide opportunity employee active contribute company inclusive culture work talent acquisition development business customer insight social community outreach company diversity goal include increase representation senior management role define individual holding vice president senior vice president title woman globally blackafrican american iii hispanicslatino december representation senior management role company woman globally blackafrican american iii hispanicslatinos addition company seek maintain exceed current inclusion index score current employee engagement index score base employee survey gender ethnicity datum woman board director women senior management role woman management role woman workforce new hire woman member underrepresented ethnic group board director member underrepresented ethnic group senior management role member underrepresented ethnic group management role member underrepresented ethnic group workforce new hire member underrepresented ethnic group selfidentifie company datum restate adjust organon spinoff senior management role define individual holding vice president senior vice president title management role define manager direct report individual hold executive vice president title compensation benefit company provide valuable suite compensation benefit program reflect commitment attract retain motivate talent support employee family stage life company continuously monitor adjust compensation benefit program ensure competitive contemporary helpful engaging support strategic imperative diversity inclusion equity flexibility quality security affordability example company regularly monitor evaluate pay practice policy ensure pay employee equitably gender race ethnicity company offer personal health care concierge service assist employee participate company medical plan health care need align business support cancer care strategy company provide enhanced cancer screening benefit cash incentive immediate access lead cancer center excellence employee high value cancer support resource caregive mental health employee family globally company implement minimum standard week pay parental leave inclusively apply parent company benefit rank quartile fortune company aon benefits index company include table content seramount previously work mother good company rank consecutive year name good company mom employee wellbee company commit help employee family improve health wellbee physical mental financial social company program ensure quality competitive value protection significant financial hardship access tool resource support employee family stage career live win company award good employer excellence health wellbeing business group health company foster array flexible work arrangement include flextime summer hour remote work telework job share parttime work help employee succeed personally professionally company overall culture wellbee offer onsite service employee thrive example include onsite health care professional major site cafeterias commit healthy menu offering onsite childcare onsite gym convenient option bank employee credit union covid response company recognize unique responsibility help response covid pandemic committed support protect employee family ensure supply medicine vaccine reach patient contribute scientific expertise development antiviral approach support health care provider community serve company continue provide employee easy regular access information include guidance hygiene measure travel good collaborate company hybrid work model example pandemic support resource program available company employee include pay continuation worker sick expose update policy enable employee medical background volunteer sarscovrelate activity resource prioritize physical mental wellness adjustment medical plan cover covidrelated diagnosis testing treatment childcare resource engage employee company strive foster employee engagement promote safe positive diverse inclusive work environment provide numerous opportunity twoway communication employee company key program initiative include promote global employee engagement survey ongoe pulse check organization interim feedback specific topic foster professional networking collaboration identify provide opportunity volunteer establish positive cooperative business relation designate employee representative talent management development company pursue goal world premier researchbase biopharmaceutical company consistent focus importance continuously develop diverse talented people company commit talent growth allow employee fluidly organization unlocking environment allow shape career pathway nonlinear inclusive opportunity experience merck current talent management system support companywide performance management leadership development talent review succession plan annual performance review help professional development company employee ensure company workforce align company objective company seeks continuously build skill capability workforce accelerate talent improve performance mitigate risk relevant continuous learning experience include limited building leadership management skill provide technical functional training employee environmental matter environmental sustainability company strive strong environmental steward realize strategy effort need continuously evolve face change climate company environmental sustainability strategy focus area drive operational efficiency design new product minimize environmental impact reduce impact company upstream downstream value chain primary focus company area climate action merck believe climate change present risk business discuss detail item risk factor table content heading climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect environmental social governance esg matter impact company business reputation potential impact climate change company business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy usage water use greenhouse gas emission company scope reduction target verify sciencebase target initiative sbti company progress climate goal aspire meet exceed evolve expectation stakeholder employee goal include achieve carbon neutrality greenhouse gas emission operation scope reduce scope operational greenhouse gas emission baseline reduce scope greenhouse gas emission baseline source purchase electricity renewable environmental sustainability initiative company include low carbon transition playbook company launch low carbon transition playbook tool intend help create site strategy identify gap uncover opportunity create common platform assessment lever resource deployment range sustainability initiative detail employee stakeholder accelerate company environmental work explanation collective benefit action business stakeholder function company expect advantage document strategize develop new way meet company broad sustainability goal streamline company track report specific metric category waste diversion playbook company create waste diversion playbook tool similar low carbon transition playbook help site selfassess develop waste diversion strategy achieve company corporate waste goal objective identify prioritize effective resource intensive action improve track report generate knowledge sharing site partner progress company value chain company signatory schneider electric energize program pioneer collaboration help pharmaceutical health care supplier address operational scope greenhouse gas emission green power procurement turn intend help signatory reduce scope emission product stewardship green sustainable science company product stewardship program focus identify prevent minimize potential safety environmental hazard product life cycle company commit understand manage reduce environmental impact product material associate discover produce company green sustainable science program use greenbydesign approach efficient innovative processing method technology company reduce energy water raw material company use companys product reduce waste company generate lower company production cost management believe expenditure relate initiative material adverse effect company financial condition result operation liquidity capital resource year environmental regulation remediation company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure material adverse effect company financial condition result operation liquidity capital resource year table content geographic area information company operation outside conduct primarily subsidiarie sale worldwide subsidiary outside percentage total company sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time available information company internet website address merckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec address website secgov addition company provide charge copy annual report include financial statement schedule write request shareholder office secretary merck inc east lincoln avenue rahway usa companys corporate governance guideline charter board director stand committee available company website httpswwwmerckcomcompanyoverviewleadershipboardofdirector information available print shareholder request company company environmental social governance esg progress report provide enhanced esg disclosure available company website httpswwwmerckcomcompanyoverviewesgesgresource information company esg progress report incorporate reference item risk factor summary risk factor company subject number risk realize materially adversely affect business result operation cash flow financial condition prospect follow summary principal risk factor face company company dependent patent right patent right invalidate circumvent business materially adversely affect company product lose market exclusivity company generally experience significant rapid loss sale product key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company expect sales lagevrio billion decline significantly approximately billion company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection company success dependent successful development marketing new product subject substantial risk company face continue pricing pressure respect product unfavorable uncertain economic condition costreduction measure take certain government negatively affect company operating result table content company face intense competition low cost generic product company face intense competition competitor product covidrelate disruption adverse impact company business operation financial performance company unable predict extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operation financial performance result operation financial condition company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect environmental social governance esg matter impact company business reputation failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company experience difficulty delay manufacture certain product include vaccine company able realize expect benefit investment emerge market ongoing war russia ukraine related global disruption adversely affect company business result operation financial condition company expose market risk fluctuation currency exchange rate interest rate pharmaceutical product develop unexpected safety efficacy concern reliance thirdparty relationship outsource arrangement materially adversely affect company business negative event animal health industry material adverse effect future result operation financial condition biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition health care industry continue subject increase regulation political action company product include product development market company obtain maintain regulatory approval development follow regulatory approval adversely affect sale company product company subject variety international law regulation company subject evolve complex tax law result additional liability affect result operation financial condition adverse outcome current future legal matter negatively affect merck business product liability insurance product limit cost prohibitive unavailable company increasingly dependent sophisticated software application compute infrastructure company target future cyberattack lead disruption worldwide operation include manufacture research sale operation social medium mobile messaging platform present risk challenge table content list exhaustive company face additional challenge risk investor carefully consider information set forth include follow risk factor decide invest company security risk factor risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation cash flow prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result risk relate company business company dependent patent right patent right invalidate circumvent business materially adversely affect patent protection consider aggregate material importance company market human health animal health product major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business successfully assert defend patent right provide market exclusivity product company involve patent dispute relate challenge patent claim party infringement company company assert defend patent outside include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic biosimilar pharmaceutical product time time file abbreviate nda blas fda seek market genericbiosimilar form company product prior expiration relevant patent own license company company normally respond assert patent lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation certain foreign market relate patent regulatory initiative result general weaken intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company launch commercially successful product replace lose sale addition product measure fair value capitalize connection acquisition experience difficulty market negatively affect product cash flow company recognize material noncash impairment charge respect value product chart list patent protection certain company market product patent protection candidate phase clinical development set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss market exclusivity material adverse effect company business cash flow result operation financial condition prospect key table content patent januvia janumet claim sitagliptin compound expire january result favorable court ruling settlement agreement relate later expire patent direct specific sitagliptin salt form product company expect product lose market exclusivity certain ruling currently appeal unfavorable court decision likely cause product lose exclusivity end company lose market exclusivity januvia janumet european country september merck expect exclusivity janumet lose european country april company lose market exclusivity januvia china approval generic equivalent product impact sale expect modest anticipate generic equivalent janumet approve china quarter impact sale expect modest product lose exclusivity company anticipate sale januvia janumet decline substantially key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company expect sales lagevrio billion decline significantly approximately billion company ability generate profit operate cash flow depend largely continue profitability company key product keytruda gardasilgardasil lynparza bravecto bridion result company dependence key product event adversely affect product market product significant adverse impact result operation financial condition event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postapproval trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale product particular sale lagevrio billion represent substantial portion company revenue profit growth company expect sales lagevrio decline significantly approximately billion company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection order remain competitive company like major pharmaceutical company continue launch new product expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop collaboration joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug vaccine result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication exist product table content sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial condition prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication anticipate labeling uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition certain collaboration failure successfully develop market new product short term long term material adverse effect company business result operation cash flow financial condition prospect company face continue pricing pressure respect product company face continue pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca inflation reduction act iii state activity aim increase price transparency include new law note item competition health care environment change health care system enact health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition large customer receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization order provide information company pricing practice company annually post website pricing transparency report report provide company average annual list price net price increase company portfolio date company gross sale reduce result rebate discount return outside numerous major market include japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product japan pharmaceutical industry subject governmentmandate annual price reduction pharmaceutical product certain vaccine furthermore government order reprice specific product determine use product exceed certain threshold define applicable repricing rule company expect pricing pressure continue future table content unfavorable uncertain economic condition costreduction measure take certain government negatively affect company operating result company business adversely affect local global economic condition include respect inflation interest rate cost raw material packaging uncertainty global economic geopolitical condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial condition prospect discuss competition health care environment global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company sale performance negatively affect costreduction measure take government party low health care cost company anticipate action additional action future negatively affect sale profit credit economic condition worsen result economic currency impact affect market globally material adverse effect company result result global macroeconomic condition company experience minor disruption volatility global supply chain network disruption increase future cause delay shipment raw material packaging relate cost inflation disruption delay cost result company inability meet demand company product company face intense competition low cost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak political pressure reduce spending prescription drug lead legislation measure encourage use generic biosimilar product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale business cash flow result operation financial condition prospect company face intense competition competitor product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use well insurance coverage reimbursement level effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial condition prospect addition product measure fair value capitalize connection acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product table content covidrelate disruption adverse impact company business operation financial performance company unable predict extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operation financial performance result operation financial condition company business financial result negatively impact covidrelated disruption start pandemic merck believe global health system patient largely adapt impact covid substantial portion merck pharmaceutical segment revenue comprise physicianadministered product adversely affect pandemic continue continued duration severity covid pandemic uncertain difficult predict degree covidrelate disruption impact company result depend future development company knowledge control include governmental thirdparty action take contain prevent spread treatment virus mitigate public health economic effect addition future pandemic epidemic similar public health threat present similar risk company business cash flow result operation financial condition prospect company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition extent company operation outside significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement include imposition trade sanction similar restriction government foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease event like result material adverse effect macroeconomic condition currency exchange rate financial market climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect company believe climate change potential negatively affect business result operation cash flow prospect company expose physical risk extreme weather condition rise sea level risk transition lowcarbon economy additional legal regulatory requirement change technology market risk reputational risk social human effect population dislocation harm health wellbeing associate climate change risk acute shortterm chronic longterm adverse impact climate change include increase frequency severity natural disaster extreme weather event hurricane tornado wildfire exacerbate drought flooding extreme heat extreme weather sealevel rise pose physical risk company facility supplier risk include loss incur result physical damage facility loss spoilage inventory business interruption cause natural disaster extreme weather event potential physical impact climate change include reduce access highquality water certain region loss biodiversity impact future product development risk disrupt company operation supply chain result increase cost new legal regulatory requirement enact prevent mitigate adapt implication change climate effect environment regulation differ jurisdiction result company subject new expand carbon pricing taxis increase compliance cost table content restriction greenhouse gas emission investment new technology increase carbon disclosure transparency investment datum gathering reporting system upgrade facility meet new building code redesign utility system increase company operating cost include cost electricity energy company company supply chain likely subject transitional risk likely pass increase cost company affect company ability procure raw material supply require operation company business quantity level require environmental social governance esg matter impact company business reputation governmental authority nongovernmental organization customer investor external stakeholder employee increasingly sensitive esg concern diversity inclusion climate change water use recyclability recoverability packaging plastic waste focus esg concern lead new requirement result increase cost associate develop manufacturing distribute companys product company ability compete affect change customer preference requirement grow demand environmentally friendly product package supplier practice failure meet customer expectation demand company strive improve esg performance set certain esg goal initiative company risk negative stockholder reaction include proxy advisory service damage brand reputation company fail meet goal initiative act responsibly company perceive act responsibly key esg area include equitable access medicine vaccine product quality safety diversity inclusion environmental stewardship support local community corporate governance transparency address human capital factor company operation respond esg consideration implementation company esg goal initiative involve risk uncertainty require investment depend thirdparty performance datum outside company control addition stakeholder disagree company esg goal initiative company meet evolve varied esg expectation investor customer stakeholder company experience reduced demand product loss customer negative impact company business result operation failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry internationally intense company sure able attract retain quality personnel cost materially increase company experience difficulty delay manufacture certain product include vaccine merck past experienced difficulty manufacture certain product include vaccine example company issue product recall zerbaxa follow identification product sterility issue company future experience difficulty delay manufacture product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include supply chain delay shortage raw material change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply previously disclose company work reduce level nitrosamine sitagliptincontaine medicine januvia difficulty reduce level achieve timely regulatory approval require change result product shortage addition company experience difficulty delay manufacturing product cause natural disaster hurricane manufacturing difficulty result product shortage lead lose sale reputational harm company table content company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market affect ability realize continued growth increase company risk exposure addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect company business china grow rapidly past year importance china company overall pharmaceutical vaccine business outside increase accordingly addition commercial operation company significant research manufacturing operation china geopolitical tension increase disrupt company operation china disruption result material adverse effect company product development sale business cash flow result operation financial condition prospect continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company currently market product absence trade impediment adverse pricing control note competition health care environment pricing pressure china increase chinese government take step reduce cost include implement health care reform lead acceleration generic substitution available mechanism drug add nrdl evolve inclusion require price negotiation impact outlook market select brand drug add nrdl average price reduction new nrdl recently complete new entry average price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution government vbp program government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semi annual process significant impact mature product move forward reason sale emerge market carry significant risk time macro economic growth select emerge market expect outpace europe lead significant increase health care spending country access innovative medicine patient failure maintain company presence emerge market material adverse effect company business cash flow result operation financial condition prospect ongoing war russia ukraine related global disruption adversely affect company business result operation financial condition ongoing war russia ukraine financial economic sanction impose country response pervasive direct indirect effect global economy adversely affect company business result operation financial condition company work crossfunctionally globe monitor mitigate interruption business continuity result war include impact merck supply chain operation clinical trial humanitarian reason company continue supply essential medicine vaccine russia work maintain compliance international sanction merck donate profit result operation russia humanitarian cause company research manufacturing facility russia currently plan investment russia suspend screen enrollment ongoing clinical trial plan new study russia company continue treat patient enrol exist clinical trial collect data study financial impact war russia ukraine immaterial company consolidate financial statement degree war relate disruption impact company result future difficult predict depend development outside company control include limited duration severity war ongoing additional financial economic sanction impose government response restriction travel regional instability geopolitical table content shift adverse effect fuel energy cost supply chain macroeconomic condition currency exchange rate financial market development negatively impact company directly indirectly party company conduct business addition effect war russia ukraine heighten risk disclose materially adversely affect company business result operation financial condition company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter business development transaction borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate inflation negatively affect company business cash flow result operation financial condition prospect order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option forwards interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful portion merck indebtedness bear interest variable interest rate primarily base london interbank offer rate libor libor subject national international regulatory guidance proposal reform cause libor cease exist entirely future company begin implement alternative reference rate alternative libor company predict consequence time additional unexpected development include increase interest expense pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action reliance thirdparty relationship outsource arrangement materially adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company thirdparty service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business negative event animal health industry material adverse effect future result operation financial condition future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal african swine fever lead widespread death precautionary destruction reduce consumption demand animal adversely affect company result operation outbreak highly contagious disease near company main production site require company immediately halt manufacture animal health product site force company incur substantial expense procure raw material product risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event addition sale bravecto billion represent approximately company animal health segment sale negative event respect bravecto material adverse effect company animal health sale animal health segment company business significant impact event future result operation significant table content biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition successful development testing manufacturing commercialization biologic vaccine particularly human animal health vaccine long complex expensive uncertain process unique risk uncertaintie relate biologic vaccine include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic vaccine subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval generally require release manufacture commercial human vaccine lot manufacture biologic vaccine especially large quantity complex require use innovative technology handle living microorganism lot approve biologic vaccine undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic vaccine frequently costly manufacture production ingredient derive live animal plant material biologic vaccine synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead variability manufacturing process lead allegation harm include infection allergic reaction allegation review standard investigation process lead closure product facility possible contamination event result substantial cost risk relate government regulation legal proceeding health care industry continue subject increase regulation political action discuss competition health care environment company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider executive branch congress state legislature congress pass inflation reduction act make significant change drug cover pay medicare program include creation financial penalty drug price rise fast rate inflation redesign medicare program require manufacturers bear liability certain drug benefit government pricesette certain medicare drug start medicare drug start addition congress pass american rescue plan act include provision eliminate statutory cap rebate drug manufacturer pay medicaid begin january rebates act discount list price eliminate cap mean manufacturer discount pay medicaid increase prior change manufacturer require pay average manufacturer price amp rebate state medicaid program medicaidcovere drug result provision begin possible manufacturer pay state medicaid programs rebate receive sale particular product change present risk merck future drug high medicaid utilization rebate exposure amp table content biden administration congress continue discuss legislation design control health care cost include cost drug company predict additional future change health care industry general pharmaceutical industry particular occur change material adverse effect company business cash flow result operations financial condition prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority include fda foreign regulatory authority include japan china fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical vaccine case fda requirement increase time resource necessary develop new product bring market regulation outside primarily focus drug safety effectiveness case reduction cost drug fda foreign regulatory authority include japan china substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent selling product jurisdiction company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval decrease demand company product include follow result postapproval phase trial study rereview product market recall loss marketing approval product market change government standard public expectation safety efficacy quality labeling change scrutiny advertising promotion withdrawal indication grant pursuant accelerate approval past clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pmda chinas nmpa increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim table content civil criminal governmental action relate product research andor marketing activity addition dissemination promotional material evolve digital channel serve increase visibility scrutiny marketplace company subject variety international law regulation company currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business cash flow result operation financial condition prospect company law regulation include additional health care reform initiative country include additional mandatory discount fee foreign corrupt practice act fcpa antibribery corruption law iii new law regulation judicial governmental decision affect pricing drug reimbursement access marketing jurisdiction change intellectual property law change accounting standard new increase datum privacy regulation enforcement particularly china vii legislative mandate preference local manufacturing pharmaceutical vaccine product viii emerge new global regulatory requirement report payment value transfer health care professional environmental regulation potential impact importation restriction embargo trade sanction legislative andor regulatory change company subject evolve complex tax law result additional liability affect result operation financial condition company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return routinely examine tax authority connection organization economic cooperation development oecd base erosion profit shift project company require disclose information tax authority operation world lead great audit scrutiny profit earn country company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition company negatively affect change tax law new tax law affect example tax rate andor revise tax law interpretation domestic foreign jurisdiction include potential change exist tax law current presidential administration congress change tax law result implementation oecd twopillar solution reform international tax landscape company take position base opinion tax counsel distribution organon common stock connection spinoff qualify transaction taxfree federal income tax purpose fact assumption representation undertaking company organon past future conduct respective business matter incorrect satisfied spinoff qualify tax free treatment result significant federal income tax liability company shareholder adverse outcome current future legal matter negatively affect merck business current future litigation claim proceeding government investigation preclude delay commercialization merck product adversely affect merck business result operation cash flow prospect financial condition legal matter include limited intellectual property dispute adverse decision litigation include product safety liability consumer protection commercial case iii antibribery regulation fcpa include compliance ongoe reporting obligation government result settlement recall withdrawal pharmaceutical product force closing manufacture plant product pricing promotional matter lawsuit claim administrative proceeding assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation vii environmental health safety sustainability matter include regulatory action response climate change viii tax liability result assessment tax authority previously disclose merck certain subsidiary defendant number lawsuit file start behalf direct indirect purchaser zetia ezetimibe allege violation federal state antitrust law state statutory common law cause action lawsuit file behalf table content twentyfive direct purchaser retailer class indirect purchaser schedule proceed trial april case plaintiff seek maximum billion damage trebling item financial statement supplementary datum note contingency environmental liability information company legal matter product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost insurance increase significantly company subject substantial number product liability claim item financial statement supplementary datum note contingency environmental liability information company current product liability litigation respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise risk relate technology company increasingly dependent sophisticated software application compute infrastructure company target future cyberattack lead disruption worldwide operation include manufacture research sale operation company increasingly dependent sophisticated software application complex information technology system compute infrastructure cloud service provider collectively system conduct critical operation certain system manage host provide party assist conduct company business disruption degradation manipulation system intentional accidental mean company employee party authorize access unauthorized party adversely affect key business process cyberattack company system party provider system cloudbase system result exposure confidential information modification critical datum andor failure critical operation misuse system result disclosure sensitive personal information theft trade secret intellectual property confidential business information company continue leverage new innovative technology enterprise replace outmoded technology improve efficacy efficiency business process include datum acquisition use create new risk aggregate impact cyberattack network disruption companys operation financial condition material date company continue target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing basis current potential threat assurance company effort protect datum system effort thirdparty provider protect system successful prevent disruption companys operation include manufacture research sale operation disruption past future result loss revenue loss critical sensitive information company company thirdparty provider database system past future result financial legal business reputational harm company substantial remediation cost social medium mobile messaging platform present risk challenge inappropriate andor unauthorized use certain social medium mobile message channel cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company product social networking platform damage company reputation brand image goodwill disclosure nonpublic companysensitive information company workforce external medium channel lead information loss internal company social medium mobile message policy guide employee appropriate personal professional use platform communication company process place completely secure protect information identify new point entry new communication tool expand present new challenge table content cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program environmental sustainability initiative include statement relate expect impact covid pandemic carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic andor biosimilar product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level price pressure abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general impact global covid pandemic future pandemic epidemic similar public health threat company business operation financial performance prospect change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product cyberattack company thirdparty provider information technology system disrupt company operation lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include china legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include law majority state require security breach notification table content change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarter currently locate kenilworth new jersey company previously announce intend consolidate new jersey campuse single corporate headquarters location rahway new jersey end company maintain operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal research facility locate rahway kenilworth new jersey west point pennsylvania boston cambridge massachusetts south san francisco california elkhorn nebraska animal health principal research facility outside locate united kingdom switzerland china mercks manufacturing operation currently headquarter rahway new jersey company production facility human health product seven location puerto rico outside subsidiary company own interest manufacturing plant property japan singapore south africa countries western europe central south america asia company subsidiarie principal facility manufacturing plant title consider satisfactory company believe property good operating condition machinery equipment maintain company believe plant manufacture product suitable intend purpose capacity project capacity include previously disclose capital expansion project adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february officer list serve pleasure board director officer elect pursuant arrangement understand officer person age office business experience robert davis chairman president chief executive officer december chief executive officer president july december executive vice president global services chief financial officer april july sanat chattopadhyay executive vice president president merck manufacturing division march richard deluca executive vice president president merck animal health september cristal downing executive vice president chief communication public affair officer august vice president medical devices global communication public affairs johnson johnson december august vice president financial communication johnson johnson january december prior senior director communications johnson johnson chirfi guindo senior vice president chief marketing officer human health july prior executive vice president head global product strategy commercialization biogen inc july july executive vice president head global marketing market access customer innovation biogen inc november june rita karachun senior vice president finance global controller march michael klobuchar executive vice president chief strategy officer july senior vice president cfo merck head global portfolio alliance management january june senior vice president corporate strategy plan president emerge business december january lisa lecointecephas senior vice president chief ethic compliance officer april executive director head global investigation february april prior senior counsel litigation government investigation bristolmyers squibb company dean executive vice president president merck research laboratory january senior vice president discovery sciences translational medicine merck research laboratory november january vice president translational medicine march november caroline litchfield executive vice president chief financial officer april senior vice president corporate treasurer january march steven mizell executive vice president chief human resource officer october prior executive vice president human resource monsanto company johanne oosthuizen senior vice president president merck human health january senior vice president head global oncology commercial january december senior vice president president msd july december joseph romanelli senior vice president president msd international human health july chief executive officer jixing pharmaceuticals july july president msd china december july david williams executive vice president chief information digital officer august act chief information digital officer december august vice president chief information officer merck animal health december jennifer zachary executive vice president general counsel corporate secretary january executive vice president general counsel april january prior partner covington burling llp table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk january approximately shareholder record company common stock issuer purchase equity security month end december follow issuer purchase equity security millions total number share total number average price purchase approximate dollar value share share pay publicly announce purchase period purchase share plan program plan programs october october november november december december total company purchase share month end december plan approve board director october purchase billion merck share treasury table content performance graph follow graph assume investment december reinvestment dividend companys common stock index composite peer group major europeanbase pharmaceutical company abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company gilead sciences inc glaxosmithkline plc novartis pfizer inc roche holding sanofi comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer group merck peer group compound annual growth rate peer group average calculate market cap weight basis december performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act item reserve table content item management discussion analysis financial condition result operation follow section generally discuss result yeartoyear comparison discussion result yeartoyear comparison include find management discussion analysis financial condition result operation item company annual report fiscal year end december file february description mercks business merck inc merck company global health care company deliver innovative health solution prescription medicine include biologic therapy vaccine animal health product company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesalers physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner spinoff organon june merck complete spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify treat taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff note consolidated financial statement table content overview financial highlight change change exclude foreign exclude foreign million share amount change exchange change exchange sale net income continue operation attributable merck inc gaap nongaap earning common share assume dilution continue operation attributable merck inc common shareholder gaap nongaap nongaap net income nongaap earning share eps exclude acquisition divestiturerelate cost restructure cost gain loss investment equity security certain item merck result prepare accordance generally accept accounting principle gaap company change treatment certain item purpose nongaap report prior period recast conform current presentation discussion reconciliation gaap nongaap net income eps nongaap income nongaap ep continue operation executive summary merck result reflect sustained strong demand company innovative product portfolio benefit patient globally enable strong operational commercial execution completion business development transaction support sciencele strategy progress pipeline therapeutic area modalitie stage development worldwide sale billion increase compare exclude unfavorable effect foreign exchange sale increase primarily growth virology drive benefit lagevrio sale oncology vaccine hospital acute care sale animal health business consistent prior year discuss covidrelated disruption negatively affect sale less extent benefit yearoveryear sale growth merck continues execute strategic business development opportunitie augment robust internal pipeline compel external science highlight activity include follow exercise option jointly develop commercialize personalize therapeutic cancer vaccine mrnav exist collaboration license agreement moderna inc moderna enter collaboration orna therapeutic orna company pioneer new investigational class engineer circular rna therapy discover develop commercialize multiple program include vaccine therapeutic area infectious disease oncology enter global codevelopment cocommercialization agreement orion corporation orion investigational candidate odm currently evaluate treatment patient metastatic castrationresistant prostate cancer mcrpc table content enter license collaboration agreement sichuan kelunbiotech biopharmaceutical ltd kelunbiotech development manufacture commercialization investigational antibody drug conjugate adc treatment solid tumor exercise option obtain exclusive license outside chinese mainland hong kong macau taiwan development manufacture commercialization kelunbiotech trophoblast antigen troptargete adc program include lead compound skb enter license collaboration agreement expand company relationship kelunbiotech pursuant merck gain exclusive right research development manufacture commercialization seven investigational preclinical adcs treatment cancer kelunbiotech retain right certain license option adcs chinese mainland hong kong macau transaction closed february enter agreement acquire imago biosciences inc imago clinical stage biopharmaceutical company develop new medicine treatment myeloproliferative neoplasm bone marrow disease acquisition closed january company receive numerous regulatory approval oncology keytruda receive approval additional indication andor internationally monotherapy therapeutic area biliary colorectal endometrial gastric melanoma small intestine renal cell cancer combination chemotherapy therapeutic area breast cervical cancer keytruda approve combination lenvima japan treatment certain adult patient radically unresectable metastatic renal cell carcinoma rcc lenvima develop collaboration eisai ltd eisai lynparza develop collaboration astrazeneca plc astrazeneca receive approval european union japan adjuvant treatment certain adult patient highrisk early breast cancer treatment certain patient mcrpc vaxneuvance vaccine help prevent pneumococcal disease approve expand indication include use infant adolescent child additionally lyfnua gefapixant approve japan adult refractory unexplained chronic cough addition lagevrio develop collaboration ridgeback biotherapeutic ridgeback receive emergency conditional approval china treatment mild moderate covid adult risk progress severe covid addition recent regulatory approval discuss company advanced latestage pipeline regulatory submission keytruda review andor internationally supplemental indication treatment certain patient hepatocellular merkel cell non smallcell lung urothelial cancer primary mediastinal bcell lymphoma pmbcl lynparza review supplemental indication japan treatment certain patient mcrpc lagevrio investigational oral antiviral covid medicine rolling review european medicine agency ema committee medicinal product human use ema recommend refusal marketing authorization merck ridgeback intend appeal gefapixant selective nonnarcotic orallyadministere investigational pxreceptor antagonist develop treatment refractory chronic cough review companys phase oncology program include keytruda therapeutic area biliary cutaneous squamous cell gastric hepatocellular mesothelioma ovarian prostate smallcell lung cancer lynparza combination keytruda nonsmallcell lung smallcell lung cancer lenvima combination keytruda colorectal esophageal gastric head neck melanoma nonsmallcell lung cancer mka coformulation quavonlimab merck novel investigational antictla antibody pembrolizumab rcc subcutaneous pembrolizumab nonsmallcell lung cancer nsclc mka subcutaneous coformulation pembrolizumab hyaluronidase nsclc mka coformulation favezelimab merck novel investigational antilag therapy pembrolizumab colorectal cancer hematological malignancy welireg rcc table content tukysa tucatinib develop collaboration seagen inc seagen breast colorectal cancer mka coformulation vibostolimab antitigit therapy pembrolizumab melanoma nonsmallcell smallcell lung cancer additionally company currently candidate phase clinical development therapeutic area include investigational valent pneumococcal conjugate vaccine prevention invasive pneumococcal disease pneumococcal pneumonia adult sotatercept treatment pulmonary arterial hypertension pah clesrovimab prevention respiratory syncytial virus mka islatravir combination doravirine treatment hiv infection partial clinical hold high dose current clinical trial lagevrio reflect phase development remain investigational follow emergency use authorization merck capital allocation priority investment business drive near longterm growth include invest opportunity address important unmet medical need support company commercial opportunity addition merck remain committed dividend continue pursue compelling external science valueenhance business development transaction research development expense reflect high clinical development spend particularly therapeutic area oncology cardiovascular infectious disease vaccine november mercks board director approve increase company quarterly dividend raising share share company outstanding common stock company return billion shareholder dividend gaap nongaap eps negatively affect respectively charge certain upfront preapproval milestone payment relate collaboration license agreement charge relate preapproval asset obtain transaction account asset acquisition war ukraine february russia invade ukraine company primary concern safety wellbee employee ensure patient customer continue access medicine vaccine need patient public health company work crossfunctionally globe monitor mitigate interruption business continuity result war include impact merck supply chain operation clinical trial humanitarian reason company continue supply essential medicine vaccine russia work maintain compliance international sanction merck donate profit table content result operation russia humanitarian cause company research manufacturing facility russia currently plan investment russia suspend screen enrollment ongoing clinical trial plan new study russia company continue treat patient enrol exist clinical trial collect data study company resource help alleviate humanitarian crisis ukraine include donation fund product financial impact war immaterial company consolidate financial statement sale russia approximately total merck consolidated sale expect decline future period company unable determine time future direct indirect impact war company business covid covidrelated disruption negative effect sale merck continue believe global health system patient largely adapt impact covid pandemic merck revenue benefit sales lagevrio billion merck expect sales lagevrio decline significantly approximately billion covidrelated disruption result estimate negative impact pharmaceutical segment sale approximately billion substantial portion pharmaceutical segment revenue comprise physicianadministere product unfavorably affect social distancing measure few visit sale benefit million lagevrio sale april merck announce discontinuing development treatment hospitalize patient covid obtain merck acquisition oncoimmune note consolidated financial statement decision result charge million cost sale operating expense reflect minor positive effect investment covidrelate research largely offset favorable impact low spending area covid pandemic march merck announce enter multiple agreement support effort expand manufacturing capacity supply sarscovcovid medicine vaccine biomedical advanced research development authority barda division office assistant secretary preparedness response department health human service provide merck million funding quarter adapt available number exist manufacturing facility production sarscovcovid vaccine medicine funding recognize reduction cost sale expect production period offset depreciation expense relate amount capitalize connection modification manufacturing facility merck johnson johnson commence arbitration dispute concern agreement pursuant merck support manufacturing supply johnson johnsons sarscovcovid vaccine vaccine drug product amount include consolidated financial statement agreement immaterial merck believe outcome arbitration material impact company financial statement price global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system enact prior year health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company sale performance negatively affect costreduction measure take government party low health care cost congress pass inflation reduction act make significant change drug cover pay medicare program include creation financial penalty drug price rise fast rate inflation redesign medicare program require manufacturers bear liability certain drug benefit government pricesette certain medicare drug start medicare drug start biden administration congress continue discuss legislation design control health care cost include cost drug company anticipate action additional action future negatively affect sale profit supply chain result global macroeconomic condition company experience minor disruption volatility global supply chain network disruption increase future cause delay shipment raw material packaging relate cost inflation table content operating result sale change change exclude foreign exclude foreign million change exchange change exchange united states international total worldwide sale grow attributable high sale virology franchise drive lagevrio contribute revenue growth high sale oncology franchise largely strong growth keytruda increase alliance revenue lenvima lynparza high sale vaccine franchise primarily attributable growth gardasilgardasil launch vaxneuvance pediatric use high sale hospital acute care product include bridion zerbaxa dificid prevymis high revenue relate thirdparty manufacture arrangement drive revenue growth discuss covidrelated disruption negative effect sale less extent benefit yearoveryear sale growth sale growth partially offset low sale diabetes product januvia janumet pneumovax vaccine virology product isentressisentress sale grow primarily drive high sale keytruda lagevrio gardasil increase alliance revenue lenvima reblozyl obtain acceleron pharma inc acceleron acquisition november launch vaxneuvance pediatric use high sale bridion welireg zerbaxa dificid increase revenue thirdparty manufacturing arrangement contribute sale growth low sale pneumovax januvia partially offset revenue growth international sale grow primarily high sale lagevrio gardasilgardasil keytruda zerbaxa increase revenue thirdparty manufacturing arrangement partially offset low sale januviajanumet simponi isentressisentress remicade pneumovax international sale represent total sale note consolidated financial statement detail sale company product discussion performance select product franchise follow pharmaceutical segment oncology change change exclude foreign exclude foreign million change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima alliance revenue reblozyl alliance revenue represent merck share profit product sale net cost sale commercialization cost note consolidated financial statement alliance revenue represent royalty include payment receive related achievement regulatory approval milestone note consolidated financial statement keytruda antipd program death receptor therapy approve monotherapy treatment certain patient cervical cancer classical hodgkin lymphoma cutaneous squamous cell carcinoma esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc nsclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer solid tumor include msihdmmr colorectal cancer msihdmmr advanced endometrial carcinoma pmbcl tumor mutational burdenhigh tmbh cancer solid tumor urothelial carcinoma include nonmuscle invasive bladder cancer additionally keytruda approve monotherapy adjuvant treatment certain patient rcc intermediatehigh high risk recurrence certain patient completely resect stage iib iic iii melanoma adjuvant treatment follow resection platinumbase chemotherapy adult patient stage iiia nsclc keytruda table content approve certain patient highrisk earlystage triplenegative breast cancer tnbc combination chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery addition keytruda approve treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy bevacizumab advanced cervical cancer combination chemotherapy esophageal cancer combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy human epidermal growth factor herpositive gastric gej adenocarcinoma combination chemotherapy hnscc combination chemotherapy locally recurrent unresectable metastatic tnbc combination axitinib advance rcc combination lenvima certain patient advance endometrial carcinoma advance rcc keytruda clinical development program include study broad range cancer type global sale keytruda grow primarily drive high demand company continue launch keytruda multiple new indication globally sale continue build multiple approve metastatic indication particular treatment certain type rcc hnscc msih cancer keytruda sale growth benefit increase uptake recent launch earlierstage indication include highrisk early stage tnbc certain type rcc melanoma keytruda sale growth international market reflect continue uptake predominately nsclc hnscc rcc indication particularly europe keytruda recently receive numerous regulatory approval summarize date approval approval monotherapy adjuvant treatment adult rcc increase risk recurrence follow nephrectomy follow january nephrectomy resection metastatic lesion base keynote trial february japans ministry health labor welfare mhlw approval combination keytruda plus lenvima radically unresectable metastatic rcc base clear study keynote trial mhlw approval treatment adult patient advance recurrent tmbh solid tumor progress chemotherapy limited february use difficult treat standard care base keynote trial food drug administration fda approval single agent treatment patient advance endometrial carcinoma msi march dmmr disease progression follow prior systemic therapy set candidate curative surgery radiation base keynote trial cohort approval combination chemotherapy bevacizumab treatment persistent recurrent metastatic cervical cancer april certain adult tumor express pdl base keynote trial approval monotherapy treatment certain adult patient unresectable metastatic msihdmmr colorectal gastric small april intestine biliary cancer advanced recurrent msihdmmr endometrial carcinoma base keynote keynote trial approval combination chemotherapy neoadjuvant treatment continue monotherapy adjuvant treatment surgery adult locally advanced earlystage tnbc high risk recurrence base keynote trial approval monotherapy adjuvant treatment adult adolescent aged year old stage iib iic melanoma undergone complete resection base keynote trial approval expand indication advance unresectable june metastatic melanoma stage iii melanoma lymph node involvement adjuvant treatment follow complete resection include adolescent patient age year old mhlw approval monotherapy adjuvant treatment certain patient rcc increase risk recurrence follow nephrectomy august follow nephrectomy resection metastatic lesion base keynote trial mhlw approval combination chemotherapy neoadjuvant treatment continue monotherapy adjuvant treatment september surgery patient hormone receptornegative hernegative breast cancer high risk recurrence base keynote trial table content mhlw approval combination chemotherapy bevacizumab treatment patient advance recurrent cervical september cancer prior chemotherapy amenable curative treatment base keynote trial mhlw approval monotherapy adjuvant treatment patient stage iib iic melanoma complete resection base september keynote trial october chinas national medical products administration nmpa approval monotherapy treatment patient hcc previously treat sorafenib oxaliplatinbase chemotherapy base keynote trial nmpa approval treatment patient highrisk earlystage tnbc tumor express pdl combination chemotherapy november neoadjuvant treatment continue monotherapy adjuvant treatment surgery base keynote trial fda approval single agent adjuvant treatment follow surgical resection platinumbase chemotherapy adult patient stage january iiia nsclc base keynote trial company party certain thirdparty license agreement pursuant company pay royalty sale keytruda term significant agreement merck pay royalty worldwide sale keytruda december party royalty decline terminate company pay additional royalty worldwide sale keytruda party termination date vary country royalty expire september vary date major european market second half royalty include cost sale lynparza oral poly adpribose polymerase parp inhibitor develop collaboration astrazeneca note consolidated financial statement lynparza approve treatment certain type advance recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancer alliance revenue relate lynparza grow largely high demand globally multiple approve indication particularly largely attributable uptake earlierstage breast cancer indication follow approval fda march lynparza receive regulatory approval summarize date approval fda approval adjuvant treatment adult patient deleterious suspect deleterious germline brcamutate hernegative march highrisk early breast cancer treat neoadjuvant adjuvant chemotherapy base olympia trial mhlw approval adjuvant treatment patient brcamutate hernegative high recurrent risk breast cancer base august olympia trial approval monotherapy combination endocrine therapy adjuvant treatment adult patient germline brca august mutation hernegative highrisk early breast cancer previously treat neoadjuvant adjuvant chemotherapy base olympia trial nmpa approval firstline maintenance treatment adult patient advance epithelial ovarian fallopian tube primary peritoneal cancer september complete partial response firstline platinumbase chemotherapy combination bevacizumab cancer associate homologous recombination deficiency hrdpositive status base paola trial approval combination abiraterone prednisone prednisolone treatment adult patient mcrpc december chemotherapy clinically indicate base propel trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai note consolidated financial statement lenvima approve treatment certain type thyroid cancer rcc hcc combination everolimus certain patient advance rcc combination keytruda certain patient advance endometrial carcinoma advance rcc alliance revenue relate lenvima grow reflect uptake advanced rcc advanced endometrial carcinoma indication particularly reblozyl firstinclass erythroid maturation recombinant fusion protein obtain merck november acquisition acceleron develop commercialize global collaboration bristol myers squibb note consolidated financial statement reblozyl approve treatment certain type anemia merck record alliance revenue million include table content royalty million receipt regulatory approval milestone payment million compare alliance revenue million vaccine change change exclude foreign exclude foreign million change exchange change exchange gardasilgardasil proquad mmr varivax pneumovax combine worldwide sale gardasil gardasil vaccine help prevent certain cancer disease cause certain type human papillomavirus hpv grew drive primarily strong demand outside particularly china benefit increase supply sale gardasil increase public sector buy pattern high pricing partially offset low demand china nmpa expand use gardasil use girl woman age vaccine previously approve use girl woman age company party certain thirdparty license agreement pursuant company pay royalty sale gardasilgardasil term significant agreement merck pay royalty worldwide sale gardasilgardasil party expire december additional royalty sale gardasilgardasil party expire december royalty include cost sale global sale proquad pediatric combination vaccine help protect measle mump rubella varicella grow primarily high pricing high demand europe worldwide sales mmr vaccine help protect measle mump rubella grow primarily high price global sale varivax vaccine help prevent chickenpox varicella grew primarily reflect high pricing partially offset low tender latin america worldwide sale pneumovax vaccine help prevent pneumococcal disease decline primarily reflect low demand market continue shift new adult pneumococcal conjugate vaccine follow change recommendation center disease control prevention cdcs advisory committee immunization practice acip company expect decline sale pneumovax continue low demand europe contribute pneumovax sale decline june fda approve expand indication vaxneuvance include use individual week age old fda approval base datum seven randomize doubleblind clinical study assess safety tolerability immunogenicity vaxneuvance infant child june cdcs acip unanimously vote include vaxneuvance recommend option vaccination infant child include routine use child year age recommendation subsequently adopt director cdc department health human service publish cdcs morbidity mortality weekly report mmwr acip unanimously vote include vaxneuvance vaccine child program october approve expand indication vaxneuvance include use infant child adolescent week year age vaxneuvance previously approve use individual year age old september vaxneuvance approve japan use adult patient vaxneuvance remain review japan use pediatric patient sale vaxneuvance million largely inventory stock merck party thirdparty licensing agreement pursuant company pay royalty net sale vaxneuvance royalty decline net sale royalty include cost sale table content hospital acute care change change exclude foreign exclude foreign million change exchange change exchange bridion prevymis dificid zerbaxa welireg calculation meaningful global sale bridion reversal type neuromuscular block agent surgery grow high demand globally particularly largely attributable bridion grow share neuromuscular blockade reversal agent increase surgical procedure bridion lose market exclusivity july company anticipate sale bridion market decline worldwide sale prevymis medicine prophylaxis prevention cytomegalovirus cmv infection disease adult cmvseropositive recipient allogenic hematopoietic stem cell transplant grow high demand globally particularly europe february fda grant priority review supplemental new drug application prevymis prophylaxis cmv disease adult kidney transplant recipient high risk prescription drug user fee act pdufa target action date june worldwide sale dificid treatment difficileassociate diarrhea grow high demand december company temporarily suspend sale zerbaxa combination antibacterial betalactamase inhibitor treatment certain bacterial infection subsequently issue product recall follow identification product sterility issue result company record intangible asset impairment charge relate zerbaxa note consolidated financial statement phase resupply zerbaxa initiate fourth quarter complete sale welireg treatment certain adult patient von hippellindau diseaseassociate rcc increase million continued uptake follow launch cardiovascular change change exclude foreign exclude foreign million change exchange change exchange alliance revenue adempasverquvo adempas alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note consolidated financial statement adempas verquvo worldwide collaboration bayer market develop soluble guanylate cyclase sgc modulator note consolidated financial statement adempas approve treatment certain type pah chronic thromboembolic pulmonary hypertension verquvo approve reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult symptomatic chronic heart failure reduce ejection fraction verquvo approve japan approve market alliance revenue collaboration essentially flat compare reflect high profit share relate adempas partially offset low profit share verquvo reflect high launch cost revenue include sale adempas verquvo merck marketing territory sale adempas merck marketing territory decline exclude unfavorable effect foreign exchange sale grew primarily reflect high demand japan table content virology change change exclude foreign exclude foreign million change exchange change exchange lagevrio isentressisentress lagevrio investigational oral antiviral covid medicine develop collaboration ridgeback note consolidated financial statement follow initial authorization certain market fourth quarter lagevrio receive multiple additional authorization worldwide increase sale lagevrio primarily reflect high sale japan launch australia december chinas nmpa grant emergency conditional approval lagevrio treatment mild moderate covid adult risk progress severe covid merck expect sales lagevrio decline significantly approximately billion reflect wane impact covid pandemic worldwide sale isentressisentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection decline low global demand reflect competitive pressure particularly europe latin america company expect competitive pressure isentressisentress continue isentressisentress lose market exclusivity july company anticipate sale decline isentressisentress market accelerate diabete change change exclude foreign exclude foreign million change exchange change exchange januviajanumet worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete decline primarily reflect loss exclusivity market europe asia pacific region lower demand sale decline partially offset increase demand latin america reflect high government tender key patent januvia janumet claim sitagliptin compound expire january result favorable court ruling settlement agreement relate later expire patent direct specific sitagliptin salt form product note consolidated financial statement company expect product lose market exclusivity certain ruling currently appeal unfavorable court decision likely cause product lose exclusivity end result competitive pressure company anticipate pricing volume decline januvia janumet company lose market exclusivity januvia janumet european country september merck expect exclusivity janumet lose european country april company lose market exclusivity januvia china approval generic equivalent product impact sale expect modest anticipate generic equivalent janumet approve china quarter impact sale expect modest combine sale januvia janumet europe china represent respectively total combine januvia janumet sale response request regulatory authority merck evaluate sitagliptincontaine product presence nitrosamine nitrosamine organic compound find trace level water food nitrosamine result chemical reaction form drug drug manufacturing process chemical structure condition drug store package company detect nitrosamine identify nitrosostg nttp batch sitagliptincontaine medicine company engage major health authority world implement additional quality control ensure portfolio sitagliptincontaine product meet health authority interim acceptable nttp limit continue distribution product market company make progress effort reduce level table content nitrosamine sitagliptincontaine medicine difficulty reduce level achieve timely regulatory approval require change result product shortage animal health segment change change exclude foreign exclude foreign million change exchange change exchange livestock companion animal sale livestock product essentially flat primarily unfavorable effect foreign exchange offset high pricing increase demand ruminant poultry product sale companion animal product decline reflect unfavorable effect foreign exchange supply constraint certain vaccine largely offset high pricing portfolio high demand bravecto line product sale billion cost expense million change change cost sale sell general administrative research development restructuring cost income expense net calculation meaningful cost sale cost sale billion billion cost sale include billion million respectively relate collaboration ridgeback lagevrio note consolidated financial statement cost sale include amortization intangible asset record connection acquisition collaboration license arrangement total billion billion amortization expense include million million respectively cumulative catchup amortization relate merck collaboration astrazeneca bayer respectively note consolidated financial statement additionally cost include charge million relate discontinuation covid development program note consolidated financial statement include cost sale expense associate restructuring activity amount million million primarily reflect accelerated depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare gross margin decline primarily reflect unfavorable impact high amortization intangible asset note high sale lagevrio revenue thirdparty manufacturing arrangement low gross margin gross margin decline partially offset favorable effect product mix foreign exchange charge relate discontinuation covid development program note sell general administrative selling general administrative sga expense billion increase compare increase primarily high administrative cost high promotional spending selling cost partially offset favorable effect foreign exchange low acquisition relate cost research development research development expense billion increase compare primarily high intangible asset impairment charge largely related nemtabrutinib high charge upfront option payment relate collaboration license arrangement high compensation table content benefit cost reflect increase headcount support expand clinical development activity increase clinical development spending increase expense partially offset charge acquisition pandion therapeutics inc pandion expense comprise cost directly incur merck research laboratory mrl company research development division focus human healthrelated activity billion billion include expense animal health research cost license cost cost incur division support activity include depreciation production general administrative aggregate billion billion decrease expense largely reflect billion charge acquisition pandion partially offset million upfront option payment aggregate collaboration licensing agreement moderna orna orion note consolidated financial statement additional information relate business development transaction expense include impairment charge billion million respectively largely related nemtabrutinib note consolidated financial statement company recognize additional impairment charge future relate cancellation delay pipeline program measure fair value capitalize connection business combination charge material expense include expense income relate change estimate fair value measurement liability contingent consideration record connection business combination company record net reduction expense million compare million expense relate change estimate restructure cost merck approve global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructuring program action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion merck expect record charge approximately million related restructuring program company anticipate action restructure program result cumulative annual net cost saving approximately million end restructuring cost primarily represent separation relate cost associate restructuring activity million million separation cost incur associate actual headcount reduction estimate expense exist severance program involuntary headcount reduction probable reasonably estimate include restructuring cost asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include cost sale sell general administrative expense research development cost company record aggregate pretax cost million million related restructuring program activity note consolidated financial statement income expense net income expense net billion expense compare billion income primarily net unrealized loss investment equity security compare net realize unrealized gain investment equity security record detail component income expense net note consolidated financial statement table content segment profit million pharmaceutical segment profit animal health segment profit nonreportable segment profit income continue operation taxis pharmaceutical segment profit comprise segment sale standard cost sga expense directly incur segment animal health segment profit comprise segment sale cost sale sga expense directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe expense incur mrl general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit cost related restructuring activity acquisition divestiturerelated cost include amortization intangible asset amortization purchase accounting adjustment intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture arrangement pharmaceutical segment profit grow primarily high sale partially offset high administrative promotional cost unfavorable effect foreign exchange animal health segment profit grow reflect low manufacturing cost partially offset high selling administrative cost unfavorable effect foreign exchange taxis income effective income tax rate continue operation tax rate continue operation reflect favorable mix income expense tax rate continue operation reflect favorable impact net unrealized loss investment equity security intangible asset impairment charge tax tax rate item reduce domestic pretax income approximately billion tax rate continue operation reflect high foreign tax credit ordinary business operation company able credit beneficial impact settlement foreign tax matter net tax benefit million relate settlement certain federal income tax matter note consolidated financial statement additionally tax rate continue operation reflect unfavorable effect charge acquisition pandion tax benefit recognize nongaap income nongaap ep continue operation nongaap income nongaap ep alternative view company performance merck provide management believe information enhance investor understand company result management use nongaap measure assess performance nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consider nonrecurre consist acquisition divestiturerelate cost restructure cost income loss investment equity security certain item exclude item significant component understanding assess financial performance nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap eps metric management use nongaap measure internally plan forecasting purpose measure performance company metric addition senior management annual compensation derive nongaap pretax income metric nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap table content comparable calculation similar measure company information nongaap income nongaap eps consider addition substitute superior net income ep prepared accordance gaap company change treatment certain item purpose nongaap report historically merck nongaap result exclude expense upfront preapproval milestone payment relate collaboration license agreement charge relate preapproval asset obtain transaction account asset acquisition extent charge consider company significant result particular period relate adjustment record subsequent period merck nongaap result long exclude charge relate item prior period recast conform current presentation reconciliation gaap financial measure nongaap financial measure continue operation follow million share amount income continue operation taxis report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost loss income investment equity security net item charge discontinuation covid development program nongaap income continue operation taxis tax income continue operation report gaap estimate tax benefit exclude item net tax benefit settlement certain federal income tax matter adjustment tax benefit record conjunction cubist pharmaceuticals inc acquisition nongaap tax income continue operation nongaap net income continue operation net income attributable noncontrolle interest report gaap nongaap net income continue operation attributable merck inc eps assume dilution continue operation report gaap ep difference nongaap ep assume dilution continue operation amount include billion million billion respectively intangible asset impairment charge estimate tax impact exclude item determine apply statutory rate originate territory nongaap adjustment acquisition divestiturerelated cost nongaap income nongaap eps exclude impact certain amount record connection acquisition divestiture business amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration exclude integration transaction certain cost associate acquisition divestiture business nongaap income nongaap eps exclude amortization intangible asset relate collaboration license arrangement restructuring cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment facility shutdown table content relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost income loss investment equity security nongaap income nongaap eps exclude realize unrealized gain loss investment equity security own directly ownership interest investment fund certain item nongaap income nongaap eps exclude certain item item adjusted evaluate individual basis consider quantitative qualitative aspect typically consist item unusual nature significant result particular period indicative future operating result exclude nongaap income nongaap eps charge relate discontinuation covid development program note consolidated financial statement net tax benefit relate settlement certain federal income tax matter note consolidated financial statement adjustment tax benefit record conjunction acquisition cubist pharmaceuticals inc research development research pipeline company currently candidate regulatory review internationally latestage clinical development chart reflect company current research pipeline february relate discussion set forth item business research development acquisition research collaboration licensing agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent transaction summarize additional detail include note consolidated financial statement merck actively monitor landscape growth opportunity meet company strategic criterion february merck kelunbiotech close license collaboration agreement expand relationship merck gain exclusive right research development manufacture commercialization seven investigational preclinical adcs treatment cancer kelunbiotech retain right research develop manufacture commercialize certain license option adcs chinese mainland hong kong macau merck upfront payment million record research development expense addition kelunbiotech eligible receive future contingent milestone payment tiere royalty future net sale commercialize adc product connection agreement merck invest million kelun biotechs series prefer share january january merck acquire imago clinical stage biopharmaceutical company develop new medicine treatment myeloproliferative neoplasm bone marrow disease billion include payment settle sharebased equity award incur approximately million transaction cost imago lead candidate bomedemstat img investigational orally available lysinespecific demethylase inhibitor currently evaluate multiple phase clinical trial treatment essential thrombocythemia myelofibrosis polycythemia vera addition indication transaction account acquisition asset merck record net asset approximately million research development expense billion relate transaction future contingent payment associate acquisition september merck exercise option jointly develop commercialize personalize therapeutic cancer vaccine mrnav pursuant term exist collaboration license agreement moderna result million charge research development expense mrna currently evaluate combination keytruda adjuvant treatment patient stage iiiiv melanoma follow complete resection phase clinical trial conduct moderna merck moderna collaborate development commercialization share cost profit equally worldwide collaboration february merck moderna announce mrnav grant breakthrough therapy designation fda adjuvant treatment patient highrisk melanoma follow complete resection august merck orna enter collaboration agreement discover develop commercialize multiple program include vaccine therapeutic area infectious disease oncology term agreement merck upfront payment orna million record research development expense addition orna eligible receive future contingent table content developmentrelate payment royalty approve product derive collaboration merck invest million ornas series prefer share july merck orion announce global codevelopment cocommercialization agreement orion investigational candidate odm drug target cytochrome cypa enzyme important steroid production oral nonsteroidal inhibitor cypa currently evaluate phase clinical trial treatment patient mcrpc merck upfront payment orion million record research development expense july merck kelunbiotech close license collaboration agreement merck gain exclusive worldwide right development manufacture commercialization investigational adc treatment solid tumor term agreement merck kelunbiotech collaborate early clinical development investigational adc merck upfront payment million record research development expense kelunbiotech eligible receive future contingent milestone payment tiere royalty future net sale connection exist arrangement merck exercise option obtain exclusive license outside chinese mainland hong kong macau taiwan development manufacture commercialization kelunbiotech troptargete adc program include lead compound skb currently phase clinical development term agreement merck kelunbiotech collaborate certain early clinical development plan include evaluate potential monotherapy combination keytruda advance solid tumor option exercise merck payment million record research development expense agree additional payment completion specify project activity technology transfer payment fund kelunbiotech ongoing research development activity addition kelunbiotech eligible receive future contingent developmental salesbase milestone payment royalty future net sale acquire inprocess research development connection business combination company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion primarily consist sotatercept billion gefapixant million nemtabrutinib million sotatercept phase clinical development company anticipate file sotatercept regulatory authority gefapixant review nemtabrutinib phase clinical development iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally iprd program require additional clinical trial datum previously anticipate program fail abandon development company recover fair value iprd record asset acquisition date circumstance occur company future operating result adversely affect company recognize impairment charge material company record iprd impairment charge research development expense billion million million respectively note consolidated financial statement additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval capital expenditure capital expenditure billion billion billion expenditure billion billion billion company plan invest approximately billion capital project approximately half relate investment include expand manufacturing capacity oncology vaccine animal health product depreciation expense billion billion billion billion billion billion relate location total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement table content analysis liquidity capital resource merck strong financial profile enable fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operating activity continue operation total debt increase work capital compare primarily increase cash investment reflect strong operating performance increase work capital compare primarily related decrease shortterm debt cash provide operating activity continue operation billion compare billion increase cash provide operating activity continue operation reflect strong operating performance cash provide operating activity continue operation reduce milestone option payment relate certain collaboration billion million cash provide operating activity continue operation continue company primary source fund finance operating need excess cash serve primary source fund finance business development transaction capital expenditure dividend pay shareholder treasury stock purchase mandatory change capitalization rule effective tax year begin december relate tax cut job act tcja increase taxis company pay begin cash investing activity continue operation billion compare billion low use cash investing activity continue operation primarily low cash acquisition partially offset high purchase security investment couple low proceed sale security investment cash financing activity continue operation billion compare cash provide financing activity continue operation billion change primarily drive cash distribution receive organon connection spinoff note consolidated financial statement proceed issuance debt compare proceed high dividend pay stockholder partially offset net repayment shortterm borrowing treasury stock purchase occur december company issue billion principal senior unsecured note consist billion note billion note billion note billion note billion note merck net proceed offer note note note note general corporate purpose include repayment outstanding commercial paper borrowing include commercial paper borrowing connection mercks acquisition acceleron indebtedness merck commit allocate equal net proceed offer note finance refinance project partnership company priority environmental social governance esg areas june company issue billion principal senior unsecured note consist billion note billion note billion note billion note merck net proceed offer general corporate purpose include repayment outstanding commercial paper borrowing indebtedness company billion note companys billion note mature accordance term repay company billion note companys billion note mature accordance term repay company billion note million floatingrate note mature accordance term repay company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility table content company expect foreseeable liquidity capital resource requirement meet exist cash cash equivalent anticipate cash flow operation commercial paper borrowing longterm borrowing need merck believe source finance adequate meet future requirement company material cash requirement arise normal course business primarily include debt obligation interest payment note consolidated financial statement detail company debt obligation timing expect future principal interest payment tax liability connection enactment tcja company require pay onetime transition tax company elect pay period year permit tcja additionally company liability unrecognize tax benefit include interest penalty note consolidated financial statement information pertain transition tax liability unrecognize tax benefit operating lease note consolidated financial statement detail companys lease obligation timing expect future lease payment contingent milestone payment company accrue liability contingent salesbase milestone payment relate collaboration astrazeneca payment deem probable company remain subject achievement relate salesbased milestone note consolidated financial statement additional information relate salesbased milestone purchase obligation purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising purchase obligation include future inventory purchase company commit connection certain divestiture december company total purchase obligation billion billion estimate payable march company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company believe maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november mercks board director increase quarterly dividend declare quarterly dividend share company outstanding common stock quarter pay january january board director declare quarterly dividend share company outstanding common stock second quarter payable april october mercks board director authorize purchase billion merck common stock treasury treasury stock purchase authorization time limit time openmarket transaction block transaction exchange privately negotiate transaction company purchase share common stock treasury program december company remain share repurchase authorization billion company anticipate make modest share repurchase program company purchase million billion common stock respectively authorize share repurchase program financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss table content foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning comprehensive income loss oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record accumulate comprehensive loss aocl reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose merck principally sell foreign currency revenue hedging program uniform weaken dollar yield large overall potential loss market value hedge instrument market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net company use balance sheet risk management program mitigate exposure asset liability effect volatility foreign exchange merck principally utilize forward exchange contract offset effect exchange develop country currency primarily euro japanese yen british pound canadian dollar australian dollar swiss franc exposure develop country currency include chinese renminbi company enter forward contract offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedging instrument forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception month cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income continue operation taxis decline approximately million million respectively company net short payable position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign table content currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow economy trkiye determine hyperinflationary consequently accordance gaap company begin remeasure monetary asset liability operation earning begin second quarter impact company result immaterial company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aocl sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal risk company currently party interest rate swap company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting estimate companys consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability business combination primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition disposition determine transaction account acquisition disposal asset business company make certain judgment include assessment input process output associate acquire set activity company determine substantially fair value gross table content asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception fair value intangible asset determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain additional marketing regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent relate patent term extension net cash flow probability adjust appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization certain company business combination involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment company determine transaction account acquisition business transaction account asset acquisition business combination goodwill record asset acquisition acquire iprd alternative future use charge expense contingent consideration recognize acquisition date table content contingent salesbase milestone term certain collaborative arrangement require company payment contingent achievement salesbase milestone sale base milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup determine probable achieve company base future sale forecast amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize remain useful life subject impairment testing revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition collection account receivable expect excess year sale record net time value money discount material provision aggregate customer discount cover chargeback rebate chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue merck remain committed program provide discount eligible cover entity note consolidated financial statement information legal proceeding company continually monitor provision aggregate customer discount material adjustment estimate associate aggregate customer discount provision table content summarize information change aggregate customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december outside variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale outside return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside payment term typically day day certain market long payment term distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial regulatory approval consider company probable company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively table content contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense continue operation million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize table content weightedaverage period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension plan total million million million net periodic benefit credit postretirement benefit plan million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset change net periodic benefit cost year year pension plan primarily attributable change discount rate additionally net periodic benefit cost reflect high settlement charge incur certain plan compare company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come discount rate company pension postretirement benefit plan range december compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum current market condition actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan compare company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact company net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact merck net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net gainloss amount primarily reflect difference expect actual return plan asset effect change actuarial assumption record component aocl expect return pension plan base calculate marketrelated value asset net gainloss amount aocl excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design streamline company cost structure result company estimate judgment future plan include future termination benefit incur conjunction involuntary separation separation probable estimable accrue termination cost company recognize range cost good estimate range range well table content estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect cost sale sell general administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible asset exclude iprd initially record fair value assign estimate useful life amortize primarily straight line basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company evaluate iprd impairment annually frequently impairment indicator exist unfavorable clinical trial datum change commercial landscape delay clinical development program relate regulatory filing approval timeline perform quantitative test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize operating result judgment evaluate impairment longlive intangible materially affect company result operation tax income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual time item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position table content likely sustain audit base technical merit tax position tax position likely sustain audit company recognize benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement recently issue accounting standard discussion recently issue accounting standard note consolidated financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program environmental sustainability initiative include statement relate expect impact covid pandemic carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense cost sale sell general administrative research development restructuring cost income expense net income continue operation taxis tax income continue operation net income continue operation net income attributable noncontrolle interest net income continue operation attributable merck inc income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder income continue operation income discontinue operation net income earning common share assume dilution attributable merck inc common shareholder income continue operation income discontinue operation net income consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive loss income net taxis net unrealized loss gain derivative net reclassification net unrealized loss investment net reclassification benefit plan net gain loss prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net taxis cash dividend declare common stock share treasury stock share purchase spinoff organon net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net taxis cash dividend declare common stock share net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity continue operation net income continue operation adjustment reconcile net income continue operation net cash provide operating activity continue operation amortization depreciation intangible asset impairment charge loss income investment equity security net charge acquisition pandion therapeutics inc charge acquisition velosbio inc defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity continue operation cash flow invest activity continue operation capital expenditure purchase seagen inc common stock purchase security investment proceed sale security investment acquisition acceleron pharma inc net cash acquire acquisition pandion therapeutics inc net cash acquire acquisition velosbio inc net cash acquire acquisition arqule inc net cash acquire acquisition net cash acquire net cash investing activity continue operation cash flow financing activity continue operation net change shortterm borrowing payment debt proceed issuance debt distribution organon purchase treasury stock dividend pay stockholder proceed exercise stock option net cash provide financing activity continue operation cash flow discontinue operation net cash provide operating activity net cash investing activity net cash financing activity net cash flow provide discontinued operation effect exchange rate change cash cash equivalent restrict cash net increase decrease cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year include restrict cash january include current asset cash cash equivalent relate discontinued operation cash cash equivalent restrict cash end year includes restrict cash december include current asset accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine include biologic therapy vaccine animal health product company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner spinoff organon june merck complete spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify treat taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff note summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination table content goodwill record asset acquisition acquire inprocess research development iprd alternative future use charge expense contingent consideration recognize acquisition date foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate result operation translate average exchange rate dollar effect arise translate net asset subsidiary change rate record comprehensive income oci remain accumulated comprehensive loss aocl sale complete substantially complete liquidation subsidiary subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost net realizable value cost substantial majority human health inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider company probable obtain regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt security classify availableforsale report fair value fair value company investment marketable debt security determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum substantially term asset liability change fair value impairment relate report net taxis oci company consider available evidence evaluate potential impairment investment marketable debt security include extent fair value cost allowance credit loss require adverse factor affect value security impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis impairment recognize earning record income expense net limited portion attribute credit loss remain portion impairment relate factor recognize oci realize gain loss debt security include income expense net investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net unrealized gain loss investment directly own determined end report period gain loss ownership interest investment fund account equity method investment report quarter lag investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine table content bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allow company recognize revenue sale vaccine government stockpile sale meet criterion revenue recognition accounting guidance customer billandhold arrangement company revenue billandhold arrangement recognize control transfer customer customer physical possession good control transfer billandhold arrangement request customer product identify belong customer ready physical transfer product direct use customer certain circumstance customer inspect accepted product company facility certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition collection account receivable expect excess year sale record net time value money discount material provision aggregate customer discount cover chargeback rebate billion billion billion chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december outside variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product outside return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside payment term typically day day certain market long payment term note disaggregate revenue disclosure table content depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development cost include property plant equipment addition company capitalize certain cost incur implement cloud computing arrangement consider service agreement include asset capitalize software cost amortize period range year long live generally associate enterprise wide project implement multiple year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible intangible acquire business combination include product product right trade name patent license initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize operating result contingent consideration certain company acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale transaction account business combination fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning significant event increase decrease probability achieve development regulatory milestone increase decrease project cash flow result correspond increase decrease fair value relate contingent consideration obligation research development research development expense incur nonrefundable advance payment good service future research development activity table content expense activity perform good receive payment research development expense include restructure cost iprd impairment charge addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration associate iprd asset research development expense include upfront milestone payment relate asset acquisition licensing transaction involve clinical development program receive regulatory approval collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner merck principal sale transaction party company recognize sale cost sale sell general administrative expense gross basis profit sharing amount pay collaborative partner record cost sale collaborative partner principal sale transaction party company record profit sharing amount receive collaborative partner alliance revenue sale alliance revenue record net cost sale include adjustment share commercialization cost partner accordance collaboration agreement adjustment determine compare commercialization cost merck incur directly report sell general administrative expense cost collaborative partner incur research development cost merck incur relate collaboration record research development expense cost reimbursement collaborative partner payment receive collaborative partner share cost pursuant term collaboration agreement record increase decrease research development expense addition term collaboration agreement require company payment base achievement certain developmental regulatory approval commercial milestone upfront milestone payment payable merck collaborative partner prior regulatory approval expense incur include research development expense payment collaborative partner subsequent regulatory approval capitalize amortize cost sale estimate useful life correspond intangible asset provide future cash flow support amount capitalize salesbased milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup determine probable achieve company amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize cost sale remain useful life subject impairment testing sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement future employee termination cost incur conjunction involuntary separation accrue separation probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income continue operation company account tax effect tax global intangible low tax income gilti certain foreign subsidiary income tax provision period tax arise company policy release disproportionate income tax effect aocl utilize itembyitem approach table content reclassification certain reclassification prior year amount conform current year presentation use estimate consolidated financial statement prepare conformity accounting principle generally accept gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability business combination primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate recently adopt accounting standard august financial accounting standard board fasb issue amend guidance accounting convertible instrument contract entity equity guidance remove separation model convertible debt instrument prefer stock amend requirement conversion option classify equity amend diluted earning share eps calculation certain convertible debt instrument company adopt new guidance january modify retrospective approach impact company consolidate financial statement adoption november fasb issue new guidance increase transparency transaction government account apply grant contribution accounting model analogy guidance require annual disclosure transaction include nature transaction significant term condition account treatment impact company financial statement company adopt new guidance january prospective basis material impact company consolidate financial statement adoption march fasb issue optional guidance ease potential burden account recognize effect reference rate reform financial reporting subsequently issue clarify amendment guidance provide optional expedient exception accounting contract hedge relationship transaction reference london interbank offer rate libor reference rate expect discontinue reference rate reform company adopt optional guidance july prospective basis material impact company consolidate financial statement adoption october fasb issue amend guidance require acquire entity recognize measure contract asset liabilitie business combination accordance exist revenue recognition guidance company adopt guidance effective january adoption guidance impact company consolidate financial statement prior acquisition impact future period dependent contract asset contract liability acquire future business combination recently issue accounting standard adopt june fasb issue guidance relate fair value measurement equity security subject contractual restriction prohibit sale equity security new guidance introduce new disclosure requirement equity security subject contractual sale restriction measure fair value amend guidance effective interim annual period apply prospectively early adoption permit interim annual period company currently evaluate impact adoption consolidate financial statement table content spinoff organon june merck complete spinoff organon distribution organon publicly trade stock company shareholder connection spinoff merck shareholder receive onetenth share organon common stock share merck common stock hold shareholder distribution expect qualify treat tax free merck shareholder federal income tax purpose indebtedness billion principal consist term loan senior note issue connection spinoff assume organon merck long obligor organon debt financing arrangement cash proceed billion distribute organon merck connection spinoff connection spinoff merck organon enter separation distribution agreement enter agreement effect spinoff provide framework relationship merck organon spinoff include transition service agreement tsa manufacturing supply agreement msa trademark license agreement intellectual property license agreement employee matter agreement tax matter agreement certain commercial agreement tsa merck provide organon service similarly organon provide merck service provision service tsa generally terminate month follow spinoff provision certain service extend month merck organon enter series interim operating agreement pursuant jurisdiction merck hold license permit right connection marketing import andor distribution organon product prior separation merck continue market import distribute product time relevant license permit transfer organon interim operating agreement accordance separation distribution agreement merck continue operation affect market behalf organon organon receive economic benefit burden activity additionally merck organon enter number msas pursuant merck manufacturing supply certain active pharmaceutical ingredient organon manufacturing supply certain formulate pharmaceutical product organon packaging label certain finished pharmaceutical product organon similarly organon merck enter number msas pursuant organon manufacturing supply certain formulate pharmaceutical product merck packaging label certain finished pharmaceutical product merck term msa range initial duration year year amount include consolidated statement income msa include sale million million respectively relate cost sale million million respectively amount include consolidated statement income tsas immaterial amount organon agreement million million december respectively reflect current asset amount organon agreement million million december respectively include accrue current liability result women health biosimilar establish brand business previously include pharmaceutical segment contribute organon spinoff interest expense relate debt issuance reflect discontinued operation company consolidated statement income income discontinue operation net taxis amount attributable noncontrolle interest period prior spinoff june merck incurred separation cost million million relate spinoff organon include income discontinue operation net taxis amount attributable noncontrolle interest cost primarily relate professional fee separation activity finance tax legal information technology function investment banking fee table content detail income discontinue operation net taxis amount attributable noncontrolle interest follow year end december sale cost expense cost sale sell general administrative research development restructuring cost income expense net income discontinue operation tax tax provision income discontinue operation net taxis income discontinue operation attributable noncontrolle interest reflect amount june spinoff date acquisition research collaboration licensing agreement company continue pursue acquisition establishment external alliance research collaboration license agreement complement internal research capability arrangement include upfront payment expense reimbursement payment party milestone royalty profit share arrangement contingent occurrence certain future event link success asset development company review market product pipeline examine candidate provide value outlicense portfolio assessment process divest certain asset pro forma financial information acquire business present historical financial result acquire entity significant compare company financial result recently complete transaction february merck sichuan kelunbiotech biopharmaceutical ltd kelunbiotech close license collaboration agreement expand relationship merck gain exclusive right research development manufacture commercialization seven investigational preclinical antibody drug conjugate adcs treatment cancer kelunbiotech retain right research develop manufacture commercialize certain license option adcs chinese mainland hong kong macau merck upfront payment million record research development expense addition kelunbiotech eligible receive future contingent developmentrelate payment aggregate billion billion regulatory milestone billion salesbase milestone kelunbiotech retain chinese mainland hong kong macau right option adcs candidate achieve regulatory approval addition kelunbiotech eligible receive tiere royalty range midsingledigit rate lowdoubledigit rate future net sale commercialize adc product connection agreement merck invest million kelunbiotech series prefer share january january merck acquire imago biosciences inc imago clinical stage biopharmaceutical company develop new medicine treatment myeloproliferative neoplasm bone marrow disease billion include payment settle sharebased equity award incur approximately million transaction cost imago lead candidate bomedemstat img investigational orally available lysinespecific demethylase inhibitor currently evaluate multiple phase clinical trial treatment essential thrombocythemia myelofibrosis polycythemia vera addition indication transaction account acquisition asset merck record net asset approximately million research development expense billion relate transaction future contingent payment associate acquisition table content transaction october merck royalty pharma plc royalty pharma enter funding arrangement royalty pharma pay merck million fund merck development cost phase trial investigational oral phosphodiesterase pdea inhibitor evaluate treatment schizophrenia royalty pharma share risk technical regulatory success merck development funding recognize merck obligation perform contractual service accordingly payment receive recognize merck reduction research development expense ratably estimate phase research period agreement royalty pharma right decisionmake authority program merck elect advance phase study royalty pharma option provide additional funding development cost million royalty pharma eligible receive royalty future sale royalty pharma elect provide additional funding note royalty pharma eligible receive future regulatory milestone payment contingent certain marketing approval high royalty rate merck record milestone payment expense income expense net receipt relate approval september merck exercise option jointly develop commercialize personalize therapeutic cancer vaccine mrnav pursuant term exist collaboration license agreement moderna inc moderna result million charge research development expense mrnav currently evaluate combination keytruda pembrolizumab merck antipd therapy adjuvant treatment patient stage iiiiv melanoma follow complete resection phase clinical trial conduct moderna merck moderna collaborate development commercialization share cost profit equally worldwide collaboration august merck orna therapeutics orna biotechnology company pioneer new investigational class engineer circular rna orna therapy enter collaboration agreement discover develop commercialize multiple program include vaccine therapeutic area infectious disease oncology term agreement merck upfront payment orna million record research development expense addition orna eligible receive future contingent developmentrelate payment aggregate million million regulatory milestone billion salesbased milestone associate progress multiple vaccine therapeutic program royaltie range highsingledigit rate lowdoubledigit rate approve product derive collaboration merck invest million ornas series prefer share july merck orion corporation orion announce global codevelopment cocommercialization agreement orion investigational candidate odm drug target cytochrome cypa enzyme important steroid production oral nonsteroidal inhibitor cypa currently evaluate phase clinical trial treatment patient metastatic castrationresistant prostate cancer merck upfront payment orion million record research development expense orion responsible manufacture clinical commercial supply addition contract provide party option convert initial codevelopment cocommercialization agreement global exclusive license merck option exercise merck assume responsibility past development commercialization expense associate program inception agreement future development commercialization expense addition orion eligible receive milestone payment associate progress development commercialization tiere doubledigit royalty sale product approve july merck kelunbiotech close license collaboration agreement merck gain exclusive worldwide right development manufacture commercialization investigational adc treatment solid tumor term agreement merck kelunbiotech collaborate early clinical development investigational adc merck upfront payment million record research development expense kelunbiotech eligible receive future contingent milestone payment aggregate million developmental milestone million regulatory milestone million salesbase milestone agreement provide merck pay tiere royalty range midsingledigit rate lowdoubledigit rate future net sale connection exist arrangement merck exercise option obtain exclusive license outside chinese mainland hong kong macau taiwan development manufacture commercialization kelunbiotech trophoblast antigen troptargete adc program include lead compound skb currently phase clinical development term agreement merck kelunbiotech collaborate certain early clinical development plan include evaluate potential monotherapy combination keytruda advance solid tumor option table content exercise merck payment million record research development expense agree additional payment million completion specify project activity million technology transfer merck agree quarterly payment aggregate million fund kelunbiotech ongoing research development activity million pay addition kelunbiotech eligible receive future contingent milestone payment include program compound aggregate million developmental milestone million commercial sale milestone million salesbase milestone agreement provide merck pay tiere royalty range midsingle digit rate lowdoubledigit rate future net sale transaction november merck acquire acceleron pharma inc acceleron publicly trade biopharmaceutical company total consideration billion acceleron development work focus evaluate transform growth factor tgfbeta superfamily protein know play central role regulation cell growth differentiation repair acceleron lead therapeutic candidate sotatercept novel mechanism action potential improve short term andor longterm clinical outcome patient pulmonary arterial hypertension pah sotatercept phase trial addon current standard care treatment pah previous agreement assume merck bristol myers squibb bms grant exclusive license develop commercialize sotatercept outside pulmonary hypertension field merck eligible receive contingent milestone royalty payment merck retain worldwide exclusive right develop commercialize sotatercept field agreement provide merck pay royalty future sale sotatercept field bms addition sotatercept acceleron portfolio include reblozyl luspatercept firstinclass erythroid maturation recombinant fusion protein approve europe certain market treatment anemia certain rare blood disorder evaluate additional indication hematology therapy reblozyl develop commercialize global collaboration bms connection ongoing collaboration merck receive sale royalty bms increase maximum base sale level royalty reduce early patent expiry generic entry indicationbyindication basis market additionally merck receive contingent regulatory milestone payment million remain eligible receive million salesbased milestone transaction account business combination company incur million cost directly relate acquisition acceleron consist primarily sharebase compensation payment settle nonveste equity award attributable postcombination service severance investment bank legal fee cost include sell general administrative expense research development cost estimate fair value asset acquire liability assume acceleron inclusive measurement period adjustment follow november cash cash equivalent investment identifiable intangible asset iprd sotatercept product product right reblozyl year useful life defer income tax liability net asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate sotatercept reblozyl determine income approach specifically multiperiod excess earning method future probability weight net cash flow discount present value utilize discount rate sotatercept reblozyl actual cash flow likely different assumed goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate pharmaceutical segment goodwill deductible tax purpose april merck acquire pandion therapeutics inc pandion clinicalstage biotechnology company develop novel therapeutic design address unmet need patient live autoimmune disease pandion development work focus advance pipeline precision immune modulator target table content critical immune control node total consideration pay billion include million cost primarily comprise sharebased compensation payment settle equity award transaction account acquisition asset merck record net asset million primarily cash research development expense billion relate transaction future contingent payment associate acquisition march merck gilead sciences inc gilead enter agreement jointly develop commercialize longacting treatment hiv combine merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir gilead investigational capsid inhibitor lenacapavir collaboration initially focus longacte oral formulation longacte injectable formulation combination product formulation potentially add collaboration mutually agree upfront payment party enter agreement term agreement merck gilead share operational responsibility development commercialization marketing cost future revenue global development commercialization cost share gilead merck oral injectable formulation program longacte oral product gilead lead commercialization merck lead commercialization rest world longacte injectable product merck lead commercialization gilead lead commercialization rest world gilead merck promote certain major market merck gilead share global product revenue equally product revenue surpass certain preagreed formulation revenue tier pass billion year net product sale oral combination revenue split adjust gilead merck revenue threshold pass billion year net product sale injectable combination revenue split adjust gilead merck revenue threshold potential combination investigational lenacapavir investigational islatravir gilead option license certain merck investigational oral integrase inhibitor develop combination lenacapavir reciprocally merck option license certain gilead investigational oral integrase inhibitor develop combination islatravir company exercise option investigational oral integrase inhibitor company follow completion phase clinical trial integrase inhibitor exercise option company split development cost revenue nonexercise company decide optout december food drug administration fda place partial clinical hold investigational new drug application certain oral implant injectable formulation islatravir base observation decrease total lymphocyte tcell count participant receive islatravir clinical study september merck announce phase clinical trial evaluate investigational oral onceweekly combination treatment regimen islatravir lenacapavir adult hiv infection virologically suppress resume amend protocol low dose islatravir investigational new drug application islatravir lenacapavir onceweekly treatment regimen remain partial clinical hold study use weekly oral islatravir dose high dose consider revise clinical program additionally merck announce discontinue development oncemonthly oral islatravir preexposure prophylaxis prep company remain committed develop compound longacte hiv prevention believe potential nucleoside reverse transcriptase translocation inhibitor nrtti mechanism january merck enter exclusive license research collaboration agreement artiva biotherapeutics inc artiva discover develop manufacture carnk cell target certain solid tumor artivas proprietary platform merck artiva agree engage different research program cover collaboration target merck sole responsibility development commercialization activity include regulatory filing approval term agreement merck upfront payment million include research development expense license right collaboration target agree upfront payment million license right collaboration target select merck accept artiva addition artiva eligible receive future contingent milestone payment span collaboration target aggregate million developmental milestone million regulatory milestone billion salesbase milestone agreement provide merck pay tiere royalty range future sale table content transaction december merck acquire oncoimmune privately hold clinicalstage biopharmaceutical company upfront payment million oncoimmune lead therapeutic candidate evaluate treatment patient hospitalize covid transaction account acquisition asset agreement prior completion acquisition oncoimmune spunout certain right asset unrelated program new entity own exist shareholder oncoimmune connection closing acquisition merck invest million ownership interest new entity value million result million premium merck recognize net liability million company record research development expense million relate transaction merck receive feedback fda additional datum need support potential emergency use authorization application company expect available half give timeline technical clinical regulatory uncertainty availability number medicine patient hospitalize covid need concentrate merck resource accelerate development manufacture viable therapeutic vaccine merck decide discontinue development treatment covid discontinuation company record charge million reflect cost sale relate fix asset material write recognition liability purchase commitment december merck acquire velosbio inc velosbio privately hold clinicalstage biopharmaceutical company billion velosbio lead investigational candidate zilovertamab vedotin adc target receptor tyrosine kinaselike orphan receptor ror currently evaluate treatment patient hematologic malignancy solid tumor transaction account acquisition asset merck record net asset million primarily cash research development expense billion relate transaction company record adjustment amount result reduction research development expense million increase total consideration pay million increase net asset record million september merck seagen inc seagen announce oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin investigational adc target liv currently phase clinical trial company equally share profit worldwide term agreement merck upfront payment million billion equity investment million share seagen common stock price share merck record million research development expense relate transaction reflect upfront payment million premium relate equity share base price seagen common stock closing date seagen eligible receive future contingent milestone payment billion include million development milestone billion salesbase milestone concurrent transaction seagen grant merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment human epidermal growth factor receptor herpositive cancer asia middle east latin america region outside canada europe merck responsible marketing application seek approval territory term agreement merck upfront payment aggregate million record research development expense seagen eligible receive future contingent regulatory approval milestone million receive tiere royalty range base annual sale level tukysa merck territory september merck acquire biologic manufacturing facility locate dunboyne ireland takeda pharmaceutical company limit million million transaction account acquisition asset merck record property plant equipment million net asset million future contingent payment associate acquisition july merck acquire right sentinel flavor tabs sentinel spectrum chew virbac corporation million sentinel product provide protection common parasite dog transaction account acquisition asset merck recognize intangible asset million relate currently market product inventory million acquisition date estimate fair value identifiable intangible asset relate currently market product determine income approach actual cash flow likely different assumed intangible asset relate currently market product amortize estimate useful life year future contingent payment associate acquisition table content july merck ridgeback biotherapeutic ridgeback closely hold biotechnology company close collaboration agreement develop lagevrio molnupiravir investigational oral antiviral covid medicine note additional information relate collaboration june merck acquire privately hold themis bioscience gmbh themis company focus vaccine include covid vaccine candidate immunemodulation therapie infectious disease cancer million acquisition originally provide merck additional contingent payment transaction account business combination company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream appropriate discount rate dependent nature time milestone payment merck recognize intangible asset iprd million cash million defer tax asset million net liability million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach january company announce discontinue development discuss result company record iprd impairment charge million research development expense company record reduction research development expense result decrease relate liability contingent consideration million company write remain iprd intangible asset relate contingent consideration liability net impact research development expense immaterial merck international aids vaccine initiative inc iavi nonprofit scientific research organization dedicate address urgent unmet global health challenge announce collaboration develop investigational vaccine sarscov study prevention covid agreement provide upfront payment merck million provide future contingent payment base sale merck sign agreement biomedical advanced research development authority barda office assistant secretary preparedness response agency department health human service provide initial funding support merck effort january company announce discontinue development discuss january company announce discontinuation development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccine discontinuation company record charge million million reflect cost sale relate fix asset material write recognition liability purchase commitment remain million cost reflect research development expense represent amount relate themis acquisition note iprd impairment charge partially offset reduction relate liability contingent consideration january merck acquire arqule inc arqule publicly trade biopharmaceutical company focus kinase inhibitor discovery development treatment patient cancer disease total consideration pay billion include million sharebased compensation payment settle equity award attributable precombination service cash pay transaction cost behalf arqule company incur million cost directly relate acquisition arqule consist entirely sharebased compensation payment settle nonveste equity award attributable postcombination service cost include sell general administrative expense arqule lead investigational candidate nemtabrutinib novel oral bruton tyrosine kinase btk inhibitor currently evaluate treatment bcell malignancy transaction account business combination table content estimate fair value asset acquire liability assume arqule follow january cash cash equivalent iprd nemtabrutinib license arrangement derazantinib defer income tax liability asset liability net total identifiable net asset goodwill consideration transfer estimate fair value nemtabrutinib determine income approach future probabilityweighte net cash flow discount present value utilize discount rate goodwill allocate pharmaceutical segment deductible tax purpose merck record intangible asset impairment charge related nemtabrutinib relate derazantinib note collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner party arrangement active participant expose significant risk reward dependent commercial success activity collaboration merck significant collaborative arrangement discuss astrazeneca merck astrazeneca plc astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer type independently merck astrazeneca develop commercialize lynparza combinations respective pdl medicine keytruda imfinzi company jointly develop commercialize astrazenecas koselugo selumetinib multiple indication term agreement astrazeneca merck share development commercialization cost lynparza koselugo monotherapy nonpdlpd combination therapy opportunitie profit lynparza koselugo product sale generate monotherapie combination therapy share equally astrazeneca principal lynparza koselugo sales transaction merck records share lynparza koselugo product sale net cost sale commercialization cost alliance revenue share development cost associate collaboration research development expense reimbursement receive astrazeneca research development expense recognize reduction research development cost agreement merck upfront payment astrazeneca payment multiyear period certain license option addition agreement provide contingent payment merck astrazeneca relate successful achievement salesbase regulatory milestone merck determine probable sale lynparza future trigger million salesbase milestone payment merck astrazeneca accordingly merck record million liability remain accrue december correspond increase intangible asset relate lynparza merck recognize million cumulative amortization catchup expense relate recognition milestone merck salesbased milestone payment astrazeneca aggregate million million respectively potential future salesbase milestone payment billion accrue deem company probable time lynparza receive regulatory approval trigger capitalize milestone payment million million respectively merck astrazeneca regulatory milestone million accrue december pay january potential future regulatory milestone payment billion remain agreement intangible asset balance relate lynparza includes capitalize salesbased regulatory milestone payment billion december include intangible net table content amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sale sell general administrative research development december receivables astrazeneca include current asset payable astrazeneca include trade account payable accrue current liability payable astrazeneca include noncurrent liability represent amortization capitalize milestone payment amount include million million respectively cumulative amortization catchup expense include accrue milestone payment eisai merck eisai ltd eisai announce strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor discover eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai record lenvima product sale globally eisai principal lenvima sale transaction merck eisai share applicable profit equally merck record share lenvima product sale net cost sale commercialization cost alliance revenue expense incur codevelopment share company accordance collaboration agreement reflect research development expense certain expense incur solely merck eisai shareable collaboration agreement include cost incur excess agree cap cost relate certain combination study keytruda lenvima agreement merck upfront payment eisai payment multiyear period certain option right final million option payment march addition agreement provide contingent payment merck eisai relate successful achievement salesbase regulatory milestone merck salesbased milestone payment eisai aggregate million million million respectively potential future salesbase milestone payment billion accrue deem company probable time lenvima receive regulatory approval trigger capitalize milestone payment million million million respectively merck eisai regulatory milestone payment remain agreement intangible asset balance relate lenvima includes capitalize salesbased regulatory milestone payment million december include intangible net amortize estimate useful life support project future cash flow subject impairment testing table content summarize financial information relate collaboration follow year end december alliance revenue lenvima cost sale sell general administrative research development december receivables eisai include current asset payable eisai include accrued current liability represent amortization capitalize milestone payment represent accrue milestone payments bayer company enter worldwide clinical development collaboration bayer bayer market develop soluble guanylate cyclase sgc modulator include bayer adempas riociguat company implement joint development commercialization strategy collaboration include development bayer verquvo vericiguat approve japan approve market agreement bayer commercialize adempas americas merck commercialize rest world verquvo merck commercialize bayer commercialize rest world company share development cost profit sale merck record sale adempas verquvo marketing territory alliance revenue alliance revenue represent merck share profit sale adempas verquvo bayer marketing territory product sale net cost sale commercialization cost cost sale include bayer share profit sale merck marketing territory addition agreement provide contingent payment merck bayer relate successful achievement salesbase milestone merck salesbased milestone payment bayer million million respectively salesbase milestone payment remain agreement intangible asset balance relate adempas includes acquire intangible asset balance capitalize salesbased milestone payment attribute adempas verquvo reflect portion final salesbase milestone payment attribute verquvo million million respectively december include intangible net asset amortize estimate useful life adempas verquvo support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue adempasverquvo net sale adempas record merck net sale verquvo record merck total sale cost sale sell general administrative research development december receivables bayer include current asset payable bayer include accrued current liability include amortization intangible asset include million cumulative amortization catchup expense december include accrue milestone payment table content ridgeback biotherapeutic july merck ridgeback closely hold biotechnology company enter collaboration agreement develop lagevrio investigational orally available antiviral candidate treatment patient covid merck gain exclusive worldwide right develop commercialize lagevrio relate molecule follow initial authorization certain market fourth quarter lagevrio receive multiple additional authorization worldwide term agreement ridgeback receive upfront payment eligible receive future contingent payment dependent achievement certain developmental regulatory approval milestone agreement provide merck reimburse ridgeback portion certain party contingent milestone payment royaltie net sale profitshare calculation merck principal sale transaction recognize sale relate cost profitshare amount record cost sale profit collaboration split equally partner reimbursement ridgeback share research development cost deduct ridgeback share profit reflect decrease research development expense summarize financial information relate collaboration follow year end december net sale lagevrio cost sale sell general administrative research development december payable ridgeback include accrued current liability include royalty expense amortization capitalize milestone payment expense period include allocation overhead charge include upfront payment include accrue royalty milestone payment bristol myers squibb reblozyl luspaterceptaamt firstinclass erythroid maturation recombinant fusion protein obtain merck november acquisition acceleron develop commercialize global collaboration bristol myers squibb bms reblozyl approve europe certain market treatment anemia certain rare blood disorder evaluate additional indication hematology therapie bms principal sale transaction reblozyl merck copromote reblozyl copromote future product approve collaboration north america reimburse bms merck receive sale royalty bms increase maximum base sale level royalty reduce early patent expiry generic entry indicationbyindication basis market additionally merck eligible receive future contingent salesbase milestone payment million merck record alliance revenue million include royalty million receipt regulatory approval milestone payment million compare alliance revenue million restructuring merck approve global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructuring program action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company estimate approximately cumulative pretax cost result cash outlay primarily relate employee separation expense facility shutdown cost approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest table content company record total pretax cost million million million related restructuring program activity inception restructuring program december merck record total pretax accumulate cost approximately billion company expect record charge approximately million related restructuring program segment report restructuring charge unallocated expense follow table summarize charge related restructuring program activity type cost separation accelerate cost depreciation total year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost separation cost associate actual headcount reduction involuntary headcount reduction probable reasonably estimate accelerated depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck recording accelerate depreciation revise useful life site asset anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include asset abandonment facility shutdown relate cost pretax gain loss result sale facility relate asset additionally activity include certain employeerelate cost associate pension postretirement benefit plan note sharebased compensation table content follow table summarize charge spend relate restructure program activity separation accelerate cost depreciation total restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december remain cash outlay expect largely complete end financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record aocl reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net company use balance sheet risk management program mitigate exposure asset liability effect volatility foreign exchange merck principally utilize forward exchange contract offset effect exchange develop country currency primarily euro japanese yen british pound canadian dollar australian dollar swiss franc exposure develop country currency include chinese renminbi table content company enter forward contract offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedging instrument forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception month cash flow contract report operating activity consolidate statement cash flow company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aocl sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci effect company net investment hedge oci consolidated statement income show pretax gain loss recognize income pretax gain loss recognize expense net amount exclude effectiveness comprehensive income testing year end december net investment hedging relationship foreign exchange contract eurodenominate note amount reclassify aocl income relate sale subsidiary interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal risk interest rate swap contract total notional billion mature swap effectively convert company billion fixedrate note billion fixedrate note variable rate debt interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow company currently party interest rate swap table content table present location amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge december cumulative fair value hedge adjustment increase include carry carry hedge liability balance sheet line item hedge item include loan payable current portion longterm debt present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative dollar derivative dollar asset liability notional asset liability notional derivative designate hedge instrument balance sheet caption interest rate swap contract current asset foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability derivative designate hedge instrument balance sheet caption foreign exchange contract current asset foreign exchange contract accrue current liability note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross amount subject offset master netting arrangement offset consolidated balance sheet cash collateral receivedposte net amount table content table provide information location pretax gain loss derivative designate fair value cash flow hedging relationship year end december financial statement caption effect fair value cash flow hedge record sale income expense net comprehensive income loss gain loss fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument impact cash flow hedging relationship foreign exchange contract gain loss recognize oci derivative increase decrease sale result aocl reclassification interest rate contract gain recognize income expense net derivative loss recognize oci derivative interest expense component income expense net table provide information income statement effect derivative designate hedge instrument derivative pretax gain loss recognize income year end december derivative designate hedge instrument income statement caption foreign exchange contract income expense net foreign exchange contract sale interest rate contract income expense net forward contract relate seagen common stock research development derivative contract primarily mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate include loss forward exchange contract enter conjunction spinoff organon derivative contract serve economic hedge forecast transaction derivative contract serve economic hedge rise treasury rate december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aocl sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information investment debt equity security december follow gross unrealized gross unrealized amortize fair amortize fair cost gain loss value cost gain loss value commercial paper government agency security corporate note bond foreign government bond total debt security publicly trade equity security total debt publicly trade equity security unrealize net loss million record income expense net equity security hold december unrealize net loss million record income expense net equity security hold december december company million million respectively equity investment readily determinable fair value include asset company record unrealize gain equity investment base favorable observable price change transaction involve similar investment investee record unrealize loss base unfavorable observable price change include income expense net company record unrealized gain million unrealize loss million relate certain equity investment hold december company record unrealized gain million unrealize loss million relate certain investment hold december cumulative unrealized gain cumulative unrealized loss base observable price change investment equity investment readily determinable fair value hold december million million respectively december company million billion million respectively record asset equity security hold ownership interest investment fund loss gain record income expense net relate investment fund billion billion million year end december respectively fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement level level level total level level level total asset investment commercial paper foreign government bond publicly trade equity security asset government agency security corporate note bond publicly trade equity security derivative asset forward exchange contract purchase currency option interest rate swap total asset liability liabilities contingent consideration derivative liability forward exchange contract write currency option total liability investment include asset restrict use include payment benefit employee benefit plan fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant december cash cash equivalent include billion billion cash equivalent respectively consider level fair value hierarchy contingent consideration summarize information change fair value liability contingent consideration associate business combination follow fair value january change estimate fair value payment fair value december record cost sale research development expense income expense net include cumulative translation adjustment december million million respectively liability relate termination sanofi pasteur msd joint venture termination merck record liability contingent future royalty payment net sale merck product previously sell joint venture december fair value liability determine utilize estimate time project cash flow riskadjusted discount rate present value cash flow balance december include million record current liability amount expect pay month payment contingent consideration year relate sanofi pasteur msd liability describe table content fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale europe china primarily drug wholesaler retailer hospital government agency company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor global economic condition include volatility associate international sovereign economy associate impact financial market business company customer large account receivable balance mckesson corporation amerisourcebergen corporation cardinal health inc represent approximately respectively total account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale company account receivable factoring agreement financial institution certain country sell account receivable company factor billion billion account receivable december respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity consolidate statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution december company collect million million respectively behalf financial institution reflect restrict cash current asset relate obligation remit cash accrue current liability company remit cash financial institution january respectively net cash flow related collection report financing activity consolidate statement cash flow cost factoring account receivable minimis derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty cash collateral advanced company counterpartie million december cash collateral receive company counterpartie million million december respectively obligation return collateral record accrue current liability table content inventory inventory december consist finished good raw material work process supply total approximate current cost decrease lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical animal health total balance january acquisition balance december balance december include cumulative translation adjustment goodwill balance accumulate goodwill impairment loss million december addition goodwill pharmaceutical segment primarily relate acquisition acceleron note acquire intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right iprd trade name license significant acquire intangible include product product right net basis relate human health market product december reblozyl billion zerbaxa million sivextro million gardasilgardasil million bridion million additionally company billion net acquire intangible related animal health december billion relate product product right billion attributable trade name primarily relate allflex december iprd primarily relate sotatercept billion obtain acquisition acceleron note gefapixant million obtain acquisition afferent pharmaceutical nemtabrutinib million obtain acquisition arqule table content note significant net intangible asset include license december include lynparza billion relate collaboration astrazeneca lenvima million relate collaboration eisai adempas million relate collaboration bayer note additional information relate intangible asset associate collaboration company record impairment charge billion cost sale relate zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infection december company temporarily suspend sale zerbaxa subsequently issue product recall follow identification product sterility issue recall constitute trigger event require evaluation zerbaxa intangible asset impairment company revise cash flow forecast zerbaxa utilize certain assumption return market timeline anticipate uptake sale revise cash flow forecast indicate zerbaxa intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate zerbaxa compare related carrying value result impairment charge note company wroteoff inventory million cost sale relate zerbaxa recall phase resupply zerbaxa initiate fourth quarter complete iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project company separate determination useful life asset begin amortization company record billion intangible impairment charge research development expense billion represent iprd impairment charge relate nemtabrutinib novel oral btk inhibitor currently evaluate treatment bcell malignancy obtain acquisition arqule note follow discussion regulatory authority quarter development period nemtabrutinib extend constitute trigger event require evaluation nemtabrutinib intangible asset impairment company estimate current fair value nemtabrutinib utilize income approach calculate present value project future cash flow market participant assumption derive forecast cash flow update reflect delay anticipate launch date nemtabrutinib result low cumulative revenue forecast reduction estimate fair value revise estimate fair value nemtabrutinib compare related carrying value result million impairment charge record quarter december regulatory authority provide additional feedback respect clinical study design lead reassessment development plan nemtabrutinib expect result change clinical study design correspond delay anticipate approval launch timeline constitute trigger event utilize income approach forecast cash flow update reflect decline forecast revenue couple increase development cost forecast reduce project cash flow lower estimate current fair value nemtabrutinib revise estimate fair value nemtabrutinib compare thenrelate carrying value result million impairment charge remain iprd intangible asset relate nemtabrutinib million assumption estimate fair value nemtabrutinib prove incorrect development nemtabrutinib progress anticipate adversely affect project future cash flow company record additional impairment charge future charge material company record million intangible asset impairment charge relate derazantinib result termination outlicense agreement decision merck pursue development derazantinib company record million iprd impairment charge related nemtabrutinib merck annual impairment assessment iprd intangible asset company estimate current fair value nemtabrutinib utilize project future cash flow market participant assumption derive forecast cash flow update reflect current competitive landscape nemtabrutinib include increase expect development cost additional clinical trial datum need develop nemtabrutinib delay anticipate launch date nemtabrutinib collectively reduce project future cash flow estimate fair value additionally discount rate utilize determine current fair value asset reduce reflect current risk profile asset revise estimate fair value nemtabrutinib compare related carrying value result iprd impairment charge note table content company record million iprd impairment charge relate decision discontinue development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccines discontinuation development program result reversal relate liability contingent consideration million iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record cost sale billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion loan payable longterm debt lease loan payable loan payable december include billion note million longdate note subject repayment option holder loan payable december include billion note million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively table content longterm debt longterm debt december consist note note note note note note note note note note note eurodenominate note note note note note note note eurodenominate note eurodenominate note eurodenominate note note note note debenture note debenture debenture note present table include borrowing variable rate result effective interest rate zero respectively exception debenture note list table redeemable merck option time vary redemption price effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply covenant december company compliance covenant aggregate maturity longterm debt year follow billion billion billion billion billion interest payment relate debt obligation follow million million million million million company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility table content lease company operating lease primarily manufacture facility research development facility corporate office employee housing vehicle certain equipment company determine arrangement lease inception evaluate contract embed lease company exercise judgment determine explicit implicit identify asset contract merck control use asset embed lease primarily associate contract manufacturing organization immaterial lease term include option extend terminate lease reasonably certain merck exercise option real estate lease facility average remain lease term seven year include option extend lease year applicable vehicle lease generally effect year company elect exclude shortterm lease lease initial term month lease asset liability balance sheet lease expense operating lease payment recognize straightline basis term lease operating lease asset liability recognize base present value lease payment lease term company lease readily determinable implicit discount rate company use incremental borrowing rate calculate present value lease payment asset class quarterly basis update incremental borrowing rate determine base average remain lease term asset class company pretax cost debt term update rate asset class apply prospectively new lease company separate lease component payment rent real estate taxis insurance cost nonlease component commonarea maintenance cost event agreement contain merck include lease nonlease component purpose calculate rightofuse asset relate lease liability nonlease component fix vehicle lease employee housing company apply portfolio approach account operating lease asset liability certain company lease agreement contain variable lease payment adjust periodically inflation actual operating expense trueup compare estimate amount amount immaterial sublease income activity relate sale leaseback transaction immaterial merck lease agreement contain material residual value guarantee material restrictive covenant operate lease cost million million million cash pay amount include measurement operating lease liability million million million operating lease asset obtain exchange lease obligation million million million supplemental balance sheet information relate operating lease follow december asset asset liability accrue current liability noncurrent liability weightedaverage remain lease term year weightedaverage discount rate include prepaid lease relate lease liability table content maturity operating lease liability follow total lease payment imputed interest december company enter additional real estate operating lease commence obligation associate lease total million contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter opinion company unlikely resolution matter material company financial condition result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability product liability litigation gardasilgardasil previously disclose merck defendant product liability lawsuit involve gardasil human papillomavirus quadrivalent type vaccine recombinant gardasil human papillomavirus valent vaccine recombinant december approximately case file pende merck federal state court action plaintiff allege thing suffer personal injury vaccination gardasil gardasil postural orthostatic tachycardia syndrome predominate allege injury august judicial panel multidistrict litigation order gardasilgardasil product liability case pende federal court nationwide transfer judge robert conrad western district north carolina coordinate pretrial proceeding few product liability case pende outside include purport class action colombia governmental proceeding previously disclose fall company receive record subpoena attorney office district vermont usao pursuant section health insurance portability accountability act hipaa relate investigation potential health care offense subpoena table content seek information relate actual potential business relationship arrangement merck practice fusion inc pfi cloudbase electronic health record ehr company acquire allscripts january company cooperate government respond subpoena subsequently merck receive second record subpoena usao broaden government information request seek information relate merck relationship ehr company shortly usao serve civil investigation demand cid merck similarly seek information company relationship ehr vendor cid explain government conduct false claim act investigation concern merck andor pfi submit claim federal health care program violate federal antikickback statute merck cooperate government investigation previously disclose april merck receive set investigative interrogatory california attorney general office pursuant investigation conduct agreement allegedly affect delay competition lantus insulin market interrogatory seek information concern merck development insulin glargine product subsequent termination merck patent litigation sanofi concern lantus resolution litigation merck cooperate california attorney general investigation previously disclose june merck receive cid department justice cid request answer interrogatory document temperature excursion thirdparty storage facility contain certain merck product merck cooperate government investigation intend produce information andor document necessary response cid previously disclose time time company subsidiary china receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate previously disclose time time company receive inquiry subject preliminary investigation activity competition governmental authority market outside authority include regulator administrative authority law enforcement similar official preliminary investigation activity include site visit formal informal request demand document material inquiry interview similar matter certain preliminary inquiry activity lead commencement formal proceeding proceeding determine adversely company monetary fine andor remedial undertaking require commercial litigation zetia antitrust litigation previously disclose merck msd schering corporation scheringplough corporation msp singapore company llc collectively merck defendant defendant number lawsuit file behalf direct indirect purchaser zetia ezetimibe allege violation federal state antitrust law state statutory common law cause action case consolidate federal multidistrict litigation zetia mdl judge rebecca beach smith eastern district virginia november direct purchaser plaintiff indirect purchaser plaintiff file motion class certification august district court grant direct purchaser motion class certification certify class direct purchaser august fourth circuit vacate district court class certification order remand proceeding consistent court rule september direct purchaser plaintiff file renew motion class certification january magistrate judge recommend district court deny motion class certification february direct purchaser plaintiff file objection recommendation april district court deny direct purchaser plaintiff renew motion class certification august district court grant certification class indirect purchasers united healthcare services inc humana inc centene corporation kaiser foundation health plan inc collectively insurer plaintiff file lawsuit jurisdiction outside eastern district virginia merck defendant make similar allegation zetia mdl additional allegation vytorin case transfer eastern district virginia proceed zetia mdl february insurer plaintiff file amend complaint march merck defendant jointly defendant move dismiss certain aspect insurer plaintiff complaint include claim vytorin damage motion dismiss vytorinrelated claim pende table content april direct purchaser plaintiff move order set deadline direct purchaser zetia currently party case file case defendant order case coordinate trial exist direct purchaser plaintiffs zetia mdl plaintiff groups court grant motion set deadline june unnamed direct purchaser file claim june new entity relate bring new complaint defendant seek intervene february district court deny merck defendant glenmark defendant motion summary judgment case file direct purchaser plaintiff retailer plaintiff indirect purchaser plaintiff plaintiff seek maximum billion damage trebling court schedule trial plaintiff plaintiff insurer plaintiff april bravecto litigation previously disclose january company serve complaint district court district new jersey follow motion practice plaintiff file second amend complaint july seek certify nationwide class action purchaser user bravecto fluralaner product territory july plaintiff contend bravecto cause neurological event dog cat allege violation new jersey consumer fraud act breach warranty product liability relate theory company move dismiss alternatively strike class allegation second amend complaint motion pende similar case file quebec canada superior court certify class dog owner quebec give bravecto chew dog february november dog experience condition postmarkete adverse reaction section label approve november company plaintiff appeal class certification decision court appeal quebec hear appeal february take matter advisement program litigation merck file complaint district court district columbia challenge letter merck receive health resource services administration hrsa mercks program integrity initiative hrsas letter merck assert merck violation statute hrsa claim continue failure provide price cover entity contract pharmacy result civil monetary penalty instance allege overcharging addition repayment instance overcharging letter similar letter hrsa send manufacturer letter hold unlawful multiple federal court merck disagree hrsas assertion merck remain committed program provide discount eligible cover entity mercks program integrity initiative consistent requirement statute intend ensure integrity sustainability statute reduce prohibit duplicate discount diversion put patient center program merck continue offer company cover outpatient drug cover entity purchase ceiling price september court stay case pende circuit rule novartis pharmaceutical corp johnson united therapeutics corp johnson qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition previously disclose putative class action lawsuit behalf direct purchaser mmr vaccine charge company misrepresent efficacy mmr vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery complete party file brief crossmotion summary judgment currently pende court merck kgaa litigation previously disclose january protect longestablished brand right company file lawsuit merck kgaa darmstadt germany kgaa historically operate emd group allege improperly use merck kgaa file suit company number jurisdiction outside allege thing unfair competition trademark infringement table content andor corporate infringement certain jurisdiction kgaa allege breach party coexistence agreement litigation ongoe trial date set ongoing jurisdiction outside patent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application nda fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire acquisition account business combination potentially significant intangible asset impairment charge bridion previously disclose january november company receive multiple paragraph certification letter hatch waxman act notify company generic drug company file application fda seek prepatent expiry approval sell generic version bridion sugammadex injection march april december company file patent infringement lawsuit district court district new jersey northern district west virginia generic company action district new jersey consolidated lawsuit assert patent cover sugammadex method sugammadex automatically stay fda approval generic application june adverse court decision whichever occur early west virginia case jointly dismiss prejudice august favor proceed new jersey remain defendant new jersey action stipulate infringement assert claim state withdraw remain claim defense defense seek shorten patent term extension sugammadex patent december district court district new jersey hold oneday trial december remain patent term extension calculation defense court order posttrial briefing defense hold closing argument february company settle generic company provide generic company bring generic version bridion market january delay applicable pediatric exclusivity early certain circumstance company agree stay lawsuit file generic company exchange agree bind judgment merit consolidate action district new jersey generic company consolidate action request dismissal action company oppose request subsequently grant court company expect company bring generic version bridion market january later depend applicable pediatric exclusivity company receive adverse court decision januvia janumet janumet previously disclose fda grant pediatric exclusivity respect januvia sitagliptin janumet sitagliptinmetformin hcl janumet sitagliptin metformin hcl extendedrelease provide month exclusivity expiration patent list fdas orange book add exclusivity term key patent protection extend exclusivity product january januvia janumet janumet contain sitagliptin phosphate monohydrate company patent cover certain phosphate salt polymorphic form sitagliptin expire include pediatric exclusivity saltpolymorph patent par pharmaceutical file suit company district court district new jersey seek declaratory judgment invalidity saltpolymorph patent response company file patent infringement lawsuit district court district delaware par pharmaceutical additional company indicate intent market generic version januvia janumet janumet follow expiration key patent protection prior expiration saltpolymorph patent later grant patent own company cover janumet formulation term plus pediatric exclusivity end company file patent infringement lawsuit mylan northern district west virginia judicial panel multidistrict litigation enter order transfer company lawsuit mylan district court district delaware coordinate consolidated pretrial proceeding case pende district prior beginning schedule october trial district court district delaware invalidity issue company settle defendant schedule participate trial company case mylan bench trial hold december district court northern district west virginia closing argument hold april september district table content court northern district west virginia issue decision company favor uphold asserted patent claim mylan viatris appeal court appeal federal circuit total company settle generic company provide generic company bring generic version januvia janumet market early certain circumstance generic version janumet market july early certain circumstance additionally mylan file petition inter part review ipr patent trademark office uspto seek invalidity claim saltpolymorph patent uspto institute ipr proceeding find reasonable likelihood challenge claim valid trial hold february final decision render hold challenge claim invalid mylan appeal usptos decision court appeal federal circuit hearing hold august september court appeal federal circuit rule company favor uphold usptos decision mylan submit combine petition panel rehear rehear banc company invite court provide response february court issue curiam decision deny rehear request march company file patent infringement lawsuit district court district delaware zydus worldwide dmcc zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus lawsuit company allege infringement saltpolymorph patent base filing zyduss nda seek approval sitagliptin tablet december party reach settlement include dismissal case prejudice enable zydu seek final approval nonautomatically substitutable product contain different form sitagliptin januvia janumet janumet result favorable court ruling settlement agreement relate later expire patent direct specific sitagliptin salt form product company expect product lose market exclusivity certain ruling currently appeal unfavorable court decision likely cause product lose exclusivity end generic company seek revocation supplementary protection certificate spc janumet number european country february finnish court refer certain question court justice european union determine validity janumet spc europe oral hearing march instance decision janumet spc find invalid germany romania upheld czech republic sweden appeal pende germany czech republic sweden company file injunctive relief belgium czech republic finland france greece hungary ireland portugal switzerland slovakia exparte preliminary injunction grant finland subsequently maintain interparte proceeding czech republic switzerland interparte preliminary injunction grant ireland preliminary injunction grant france validity spc associated patent hold prima facie valid preliminary injunction refuse portugal greece belgium hungary belgium company file main infringement action generic company request preliminary measure action refuse lynparza december astrazeneca pharmaceutical receive paragraph certification letter hatchwaxman act notify astrazeneca natco pharma limited natco file application fda seek prepatent expiry approval sell generic version lynparza olaparib tablet february astrazeneca company file patent infringement lawsuit district court district new jerseydelaware natco lawsuit assert patent cover olaparib automatically stay fda approval generic application june adverse court decision whichever occur early litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial condition result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company table content cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial condition result operation liquidity company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee table content nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus psus dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period subject term applicable award psu award generally vest year rsu award generally vest onethird year threeyear period total pretax sharebase compensation cost record million million million respectively amount include million million respectively relate continue operation income tax benefit sharebase compensation expense recognize million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree interest rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december vest expect vest december exercisable december table content additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december expect vest december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expenses pension postretirement benefit plan company define benefit pension plan cover eligible employee certain international subsidiary addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plan include certain cost report discontinue operation consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset amortization unrecognize prior service cost net loss gain amortization termination benefit curtailment settlement net periodic benefit cost credit net periodic benefit cost credit pension postretirement benefit plan include expense curtailment settlement termination benefit provide certain employee connection spinoff organon connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment settlement record certain pension plan increase lump sum payment pension plan participant contribute settlement record table content component net periodic benefit cost credit service cost component include income expense net note exception certain amount termination benefit curtailment settlement record restructuring cost event give rise termination benefit curtailment settlement related restructuring action income discontinue operation net taxis amount attributable noncontrolle interest relate spinoff organon note obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement spinoff organon fair value plan asset december benefit obligation january service cost interest cost actuarial gain loss benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement spinoff organon benefit obligation december fund status december recognize asset accrue current liability noncurrent liability actuarial gain loss primarily reflect change discount rate december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total pension plan cash cash equivalent investment fund develop market equities emerge market equity real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment derivative plan asset fair value international pension plan cash cash equivalent investment fund develop market equity government agency obligation emerge market equities corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december plans level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale net balance december international pension plan balance january actual return plan asset relate asset hold december purchase sale net transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total cash cash equivalent investment fund develop market equities emerge market equity real estate government agency obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment derivative plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation table content return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution contribution expect approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net gainloss amount reflect difference expect actual return plan asset effect change actuarial assumption net gainloss amount excess certain threshold amortize net periodic benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net loss gain arise period prior service cost credit arise period net loss gain amortization include benefit cost prior service credit amortization include benefit cost settlement curtailment table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate interest credit rate benefit obligation discount rate salary growth rate interest credit rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis expect rate return plan develop consider longterm historical return data current market condition actual return plan asset reference information longterm return expectation asset category weightedaverage expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan compare health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate saving plan company maintain define contribution saving plan company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss loss income investment equity security net net periodic define benefit plan credit cost service cost net include net realize unrealized gain loss investment equity security own directly ownership interest investment fund unrealize gain loss investment directly own determined end report period gain loss ownership interest investment fund account quarter lag company estimate gain approximately million record quarter ownership interest investment fund interest pay million million million taxis income reconciliation effective tax rate income continue operation statutory rate follow tax rate tax rate tax rate statutory rate apply income continue operation taxis differential arise foreign earning gilti foreignderive intangible income deduction state taxis tax credit tax settlement valuation allowance restructure acquisition velosbio acquisition pandion acquisition oncoimmune applicable impact change uncertain tax position reflect reconcile item company remain transition tax liability tax cut job act tcja reduce payment utilization foreign tax credit billion december million include income taxis payable remainder billion include noncurrent liability result transition tax tcja company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign withholding taxis apply company remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate particularly ireland switzerland singapore puerto rico operate tax incentive grant begin expire yield table content favorable impact effective tax rate compare statutory rate company additional cantonal tax holiday switzerland provide tax rate reduction effective income continue operation taxis consist year end december domestic foreign taxis income continue operation consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability product intangible license capitalization inventory relate accelerated depreciation equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis company net operating loss nol carryforward jurisdiction december million defer tax asset nol carryforward relate foreign jurisdiction valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward table content nol carryforward valuation allowance million establish tax credit carryforward nol carryforward income taxis pay include amount attributable discontinue operation billion billion billion respectively income taxis pay consist year end december domestic foreign include tcja transition tax payment tax benefit relate stock option exercise million million million reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation spinoff organon balance december reflect settlement irs discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease approximately million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount expense benefit million million million amount reflect beneficial impact tax settlement include settlement discuss liability accrue interest penalty million million december respectively internal revenue service irs conclude examination merck federal income tax return result company require payment million million related continue operation million relate discontinued operation company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record million net tax benefit million relate continue operation million relate discontinued operation net benefit reflect reduction reserve unrecognize tax benefit relate liability tax position relate year examination irs currently conduct examination company tax return year addition state foreign tax examination progress jurisdiction company income tax return open examination period table content earning share calculation earning share share millions follow year end december net income continue operation attributable merck inc income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck inc common shareholder income continue operation income discontinue operation net income earning common share assume dilution attributable merck inc common shareholder income continue operation income discontinue operation net income issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss change component comprehensive income loss follow employee foreign currency benefit translation accumulate derivative investment plan adjustment comprehensive loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis spinoff organon note balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis primarily relate foreign currency cash flow hedge reclassify aocl sale represent net realize gain sale availableforsale debt security reclassify aocl income expense net include net amortization prior service cost actuarial gain loss settlement curtailment include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table content segment reporting company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sale center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter table content sale company product follow year end december intl total intl total intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima alliance revenue reblozyl vaccine gardasilgardasil proquadmmr iivarivax rotateq pneumovax vaqta hospital acute care bridion prevymis dificid primaxin noxafil invanz cancidas zerbaxa cardiovascular alliance revenue adempasverquvo adempas virology lagevrio isentressisentress neuroscience belsomra immunology simponi remicade diabete januvia janumet pharmaceutical total pharmaceutical segment sale animal health livestock companion animal total animal health segment sale segment sale total segment sale plus international equal total round alliance revenue lynparza lenvima represent merck share profit product sale net cost sale commercialization cost note alliance revenue reblozyl represent royalty include payment receive related achievement regulatory approval milestone note alliance revenue adempasverquvo represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent sale healthcare service segment business healthcare service segment fully divest quarter primarily comprise miscellaneous corporate revenue include revenue hedging activity increase decrease sale million million million respectively revenue thirdparty manufacturing arrangement include sale organon include million million million respectively relate upfront milestone payment receive merck outlicense arrangement table content consolidated sale geographic area derive follow year end december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profit income continue operation taxis follow year end december segment profit pharmaceutical segment animal health segment segment total segment profit profit unallocate interest income interest expense amortization depreciation research development restructuring cost unallocate net pharmaceutical segment profit comprise segment sale standard cost sell general administrative expense directly incur segment animal health segment profit comprise segment sale cost sale sell general administrative expense research development cost directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur merck research laboratory companys research development division focus human healthrelated activity general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization intangible asset purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacture arrangement unallocate net include expense corporate manufacturing cost center goodwill intangible asset impairment charge gain loss sale business expense income relate change estimate fair value measurement liability contingent consideration miscellaneous income expense item table content equity incomeloss affiliate depreciation include segment profit follow pharmaceutical animal health total year end december include segment profit equity income affiliate depreciation year end december include segment profit equity income affiliate depreciation year end december include segment profit equity loss affiliate depreciation property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific china japan latin america china japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director stockholders merck inc opinion financial statement internal control financial reporting audit accompany consolidated balance sheet merck inc subsidiary company december relate consolidated statement income comprehensive income equity cash flow year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report internal control financial reporting appear item responsibility express opinion company consolidate financial statement companys internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate table content critical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate rebate accrual medicaid manage care medicare describe note consolidated financial statement company record certain variable consideration include discount estimate time sale generally expect value method amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue certain discount represent portion accrual form rebate amount owe base definitive contractual agreement legal requirement private sector manage care public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider management use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision accrue balance relative provision rebate include accrue current liability billion december majority relate rebate accrual medicaid manage care medicare principal consideration determination perform procedure relate rebate accrual medicaid manage care medicare critical audit matter significant judgment management significant measurement uncertainty involve develop rebate accrual accrual base assumption develop pricing information historical customer segment utilization mix high degree auditor judgment subjectivity effort perform procedure evaluate evidence relate assumption address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate rebate accrual medicaid manage care medicare include management control assumption estimate correspond rebate accrual procedure include develop independent estimate rebate accrual utilize party datum historical customer segment utilization mix pricing information term specific rebate program historical trend actual rebate claim pay compare independent estimate rebate accrual record management iii testing rebate claim pay include evaluate claim consistency contractual term company rebate agreement pricewaterhousecooper llp florham park new jersey february serve company auditor table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective fourth quarter change internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control table content inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear robert davis caroline litchfield chairman president chief executive officer executive vice president chief financial officer item information item disclosure foreign jurisdiction prevent inspection applicable table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document require information compliance section securities exchange act applicable incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website merckcomcompanyoverviewcultureandvaluescode ofconductvaluesandstandard company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table ceo pay ratio pay performance table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate schedule director fee table director compensation table company proxy statement annual meeting shareholder hold require information heading compensation management development committee interlock insider participation compensation management development committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck inc incentive stock plan merck inc nonemployee directors stock option plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item